Identification

Name
Codeine
Accession Number
DB00318  (APRD00120, DB09471)
Type
Small Molecule
Groups
Approved, Illicit
Description

An opioid analgesic related to morphine but with less potent analgesic properties and mild sedative effects. It also acts centrally to suppress cough.

Structure
Thumb
Synonyms
  • (−)-Codeine
  • (5alpha,6alpha)-7,8-Didehydro-4,5-epoxy-3-methoxy-17-methylmorphinan-6-ol
  • (5α,6α)-7,8-didehydro-4,5-epoxy-3-methoxy-17-methylmorphinan-6-ol
  • 3-Methylmorphin
  • 3-methylmorphine
  • 7,8-didehydro-4,5alpha-epoxy-3-methoxy-17-methylmorphinan-6alpha-ol
  • 7,8-didehydro-4,5α-epoxy-3-methoxy-17-methylmorphinan-6α-ol
  • Codein
  • Codeína
  • Codéine
  • Codeine anhydrous
  • Codeine polistirex
  • Codeinum
  • L-Codeine
  • Methylmorphine
  • morphine 3-methyl ether
  • Morphine monomethyl ether
  • morphine monomethyl ether
  • morphine-3-methyl ether
  • O(3)-methylmorphine
External IDs
IDS-NC-005(SECT.-2)
Product Ingredients
IngredientUNIICASInChI Key
Codeine hydrochloride406LPJ779Q1422-07-7NUXLENPAZQNFAM-FFHNEAJVSA-N
Codeine monohydrateQ830PW75206059-47-8WRRSFOZOETZUPG-FFHNEAJVSA-N
Codeine phosphate2X585M1M3T52-28-8WUXLCJZUUHIXFY-FFHNEAJVSA-N
Codeine phosphate hemihydrateGSL05Y1MN641444-62-6DKSZLDSPXIWGFO-BLOJGBSASA-N
Codeine sulfateAVW5HY4N2E1420-53-7BCXHDORHMMZBBZ-DORFAMGDSA-N
Codeine sulfate trihydrate11QV9BS0CB6854-40-6BOLDZXRCJAJADM-AAXBYHQXSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Codeine 15Tablet15 mgOralLaboratoire Riva Inc1994-12-31Not applicableCanada
Codeine 30Tablet30 mgOralLaboratoire Riva Inc1994-12-31Not applicableCanada
Codeine Contin 100mg Controlled Release TabTablet, extended release100 mgOralPurdue Pharma1995-12-31Not applicableCanada
Codeine Contin 150mg Controlled Release TabTablet, extended release150 mgOralPurdue Pharma1995-12-31Not applicableCanada
Codeine Contin 200mg Controlled Release TabTablet, extended release200 mgOralPurdue Pharma1995-12-31Not applicableCanada
Codeine Contin 50mg Controlled Release TabTablet, extended release50 mgOralPurdue Pharma1997-03-13Not applicableCanada
Codeine Phosphate Inj 30mg/mlSolution30 mgIntramuscular; SubcutaneousHospira, Inc.1981-12-31Not applicableCanada
Codeine Phosphate Inj 60mg/mlSolution60 mgIntramuscular; SubcutaneousHospira, Inc.1981-12-31Not applicableCanada
Codeine Phosphate Injection USPLiquid30 mgIntramuscular; SubcutaneousSandoz Canada Incorporated1978-12-31Not applicableCanada
Codeine Phosphate SyrupSyrup25 mgOralLaboratoire Atlas Inc1986-12-18Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Acetaminophen and Codeine PhosphateTablet300 mg/1OralRemedy Repack2013-04-042017-01-20Us
Codeine SulfateTablet60 mg/1OralLannett Company, Inc.2014-06-13Not applicableUs
Codeine SulfateTablet30 mg/1OralLannett Company, Inc.2014-06-13Not applicableUs
Codeine SulfateTablet15 mg/1OralLannett Company, Inc.2014-06-13Not applicableUs
PMS-codeineTablet30 mgOralPharmascience Inc2001-12-16Not applicableCanada
PMS-codeineTablet15 mgOralPharmascience Inc2001-11-16Not applicableCanada
Ratio-codeineSyrup5 mgOralTeva1977-12-312017-05-01Canada
Teva-codeineTablet30 mgOralTeva1983-12-31Not applicableCanada
Teva-codeineTablet15 mgOralTeva1983-12-31Not applicableCanada
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
(extra Strength) Acetaminophen, Caffeine & 8mg Codeine Phosphate CapletsCodeine phosphate (8 mg) + Acetaminophen (500 mg) + Caffeine (15 mg)TabletOralStanley Pharmaceuticals, A Division Of Vita Health Products Inc.1998-07-222002-07-31Canada
222 TabletsCodeine phosphate (8 mg) + Acetylsalicylic acid (375 mg) + Caffeine citrate (30 mg)TabletOralMcneil Consumer Healthcare Division Of Johnson & Johnson Inc1951-12-312015-08-17Canada
282 Mep TabCodeine phosphate (15 mg) + Acetylsalicylic acid (350 mg) + Caffeine citrate (30 mg) + Meprobamate (200 mg)TabletOralMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1959-12-311998-08-14Canada
282 TabCodeine phosphate (15 mg) + Acetylsalicylic acid (375 mg) + Caffeine citrate (30 mg)TabletOralMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1951-12-311998-04-21Canada
282 TabletsCodeine phosphate (15 mg) + Acetylsalicylic acid (375 mg) + Caffeine citrate (30 mg)TabletOralPendopharm Division Of De Pharmascience Inc1998-11-01Not applicableCanada
292 TabCodeine phosphate (30 mg) + Acetylsalicylic acid (375 mg) + Caffeine citrate (30 mg)TabletOralMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1951-12-311998-08-14Canada
292 TabletsCodeine phosphate (30 mg) + Acetylsalicylic acid (375 mg) + Caffeine citrate (30 mg)TabletOralPendopharm Division Of De Pharmascience Inc1998-10-01Not applicableCanada
A & C Tablets With Codeine 15mgCodeine phosphate (15 mg) + Acetylsalicylic acid (375 mg) + Caffeine (15 mg)TabletOralD.C. Labs Limited1971-12-312003-07-11Canada
A & C Tablets With Codeine 30mgCodeine phosphate (30 mg) + Acetylsalicylic acid (375 mg) + Caffeine (15 mg)TabletOralD.C. Labs Limited1971-12-312003-07-11Canada
A.C. & C. 8 mgCodeine phosphate (8 mg) + Acetylsalicylic acid (375 mg) + Caffeine (15 mg)TabletOralLaboratoires Confab IncNot applicableNot applicableCanada
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
AiracofCodeine phosphate (7.5 mg/5mL) + Diphenhydramine hydrochloride (12.5 mg/5mL) + Phenylephrine hydrochloride (7.5 mg/5mL)LiquidOralCenturion Labs2010-01-082016-10-13Us
ExeClear CCodeine phosphate (10 mg/5mL) + Guaifenesin (2 mg/5mL)LiquidOralLarken Laboratories, Inc.2008-10-172015-12-29Us
Guaifenesin ACCodeine phosphate (10 mg/5mL) + Guaifenesin (100 mg/5mL)SyrupOralRising Pharmaceuticals2009-09-22Not applicableUs
Guaifenesin DACCodeine phosphate (10 mg/5mL) + Guaifenesin (100 mg/5mL) + Pseudoephedrine hydrochloride (30 mg/5mL)LiquidOralRising Pharmaceuticals2009-09-28Not applicableUs
Lexuss 210Codeine phosphate (10 mg/5mL) + Chlorpheniramine maleate (2 mg/5mL)LiquidOralCenturion Labs2009-04-152017-08-17Us
Notuss-NXCodeine phosphate (10 mg/5mL) + Chlorcyclizine Hydrochloride (9.375 mg/5mL)LiquidOralSj Pharmaceuticals, Llc2010-11-032017-08-17Us
Notuss-NXDCodeine phosphate (10 mg/5mL) + Chlorcyclizine Hydrochloride (9.375 mg/5mL) + Pseudoephedrine hydrochloride (30 mg/5mL)LiquidOralSj Pharmaceuticals, Llc2010-11-032017-09-28Us
Theracodeine-300Codeine phosphate + Acetaminophen + gamma-Aminobutyric acidKitOralPhysician Therapeutics Llc2011-02-152016-10-13Us
Zotex-CCodeine phosphate (10 mg/5mL) + Mepyramine maleate (5 mg/5mL) + Phenylephrine hydrochloride (5 mg/5mL)SyrupOralVertical Pharmaceuticals, Inc.2008-10-102017-03-01Us
International/Other Brands
Actacode (Sigma) / Bisoltus (Boehringer Ingelheim) / Bromophar (Qualiphar) / Bronchicum (Sanofi-Aventis) / Bronchodine (Pharmacobel) / Codant (Antigen) / Codedrill (Pierre Fabre) / Codein (Cristália) / Codeisan (Belmac) / Coderpina (Frycia Centro América) / Codicalm (Welti) / Codicept / Codinex (Pinewood) / Coducept / Cougel (Hwang's) / Coutan (Mey See) / Dinco (Center) / Farmacod (Farmacom) / Galcodine (Thornton & Ross) / Pectoral (Siphat) / Tussoret (MaxMedic)
Categories
UNII
UX6OWY2V7J
CAS number
76-57-3
Weight
Average: 299.3642
Monoisotopic: 299.152143543
Chemical Formula
C18H21NO3
InChI Key
OROGSEYTTFOCAN-DNJOTXNNSA-N
InChI
InChI=1S/C18H21NO3/c1-19-8-7-18-11-4-5-13(20)17(18)22-16-14(21-2)6-3-10(15(16)18)9-12(11)19/h3-6,11-13,17,20H,7-9H2,1-2H3/t11-,12+,13-,17-,18-/m0/s1
IUPAC Name
(1S,5R,13R,14S,17R)-10-methoxy-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0¹,¹³.0⁵,¹⁷.0⁷,¹⁸]octadeca-7(18),8,10,15-tetraen-14-ol
SMILES
[H][C@@]12OC3=C(OC)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O

Pharmacology

Indication

For treatment and management of pain (systemic). It is also used as an antidiarrheal and as a cough suppressant.

Associated Conditions
Pharmacodynamics

Codeine, an opiate agonist in the CNS, is similar to other phenanthrene derivatives such as morphine. It is selective for the mu receptor, but with a much weaker affinity than morphine. The analgesic properties of codeine have been speculated to come from its conversion to morphine. The principle therapeutic action is analgesia. Codeine concentrations do not correlate with brain concentration or relief of pain. The minimum effective concentration is highly variable is influenced by numerous factors, including but not limited to, age, previous opioid use, age, and general medical condition. However, the effective dose for patients that have developed tolerance is significantly higher than the opioid-naive patients.

Mechanism of action

Opiate receptors are coupled with G-protein receptors and function as both positive and negative regulators of synaptic transmission via G-proteins that activate effector proteins. Binding of the opiate stimulates the exchange of GTP for GDP on the G-protein complex. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine and noradrenaline is inhibited. Opioids also inhibit the release of vasopressin, somatostatin, insulin and glucagon. Codeine's analgesic activity is, most likely, due to its conversion to morphine. Opioids close N-type voltage-operated calcium channels (OP2-receptor agonist) and open calcium-dependent inwardly rectifying potassium channels (OP3 and OP1 receptor agonist). This results in hyperpolarization and reduced neuronal excitability.

TargetActionsOrganism
AMu-type opioid receptor
partial agonist
Human
AKappa-type opioid receptor
partial agonist
Human
ADelta-type opioid receptor
agonist
Human
Absorption

Well absorbed following oral administration with a bioavailability of approximately 90%. Maximum plasma concentration occurs 60 minutes post-administration. Food does not effect the rate or extent of absorption of codeine.

Volume of distribution

Apparent volume of distribution = 3-6 L/kg

Protein binding

7-25% bound to plasma proteins.

Metabolism

Hepatic. Codeine is a prodrug, itself inactive, but demethylated to the active morphine by the liver enzyme CYP2D6 to morphine. 70-80% of the dose undergoes glucuronidation to form codeine-6-glucuronide. This process is mediated by UDP-glucuronosyltransferase UGT2B7 and UGT2B4. 5-10% of the dose undergoes O-demethylation to morphine and 10% undergoes N-demethylation to form norcodeine. CYP2D6 mediates the biotransformation to morphine. CYP3A4 is the enzyme that mediates the conversion to norcodiene. Morphine and norcodeine are further metabolized and undergo glucuronidation. The glucuronide metabolites of morphine are morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G). Both morphine and morphine-6-glucuronide are active and have analgesic activity. Norcodiene and M3G do not have any analgesic properties.

Route of elimination

90% of the total dose of codeine is excreted through the kidneys, of which 10% is unchanged codeine.

Half life

Plasma half-lives of codeine and its metabolites have been reported to be approximately 3 hours.

Clearance
Not Available
Toxicity

Respiratory depression, sedation and miosis and common symptoms of overdose. Other symptoms include nausea, vomiting, skeletal muscle flaccidity, bradycardia, hypotension, and cool, clammy skin. Apnea and death may ensue.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Codeine Action PathwayDrug action
Codeine Metabolism PathwayDrug metabolism
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Cytochrome P450 2D6CYP2D6*4(A;A)A Allele, homozygoteEffect Directly StudiedPatients with this genotype have reduced metabolism of codeine.Details
Cytochrome P450 2D6CYP2D6*6(-;-)T deletion, homozygoteEffect Directly StudiedPatients with this genotype have reduced metabolism of codeine.Details
Cytochrome P450 2D6CYP2D6*5Not AvailableWhole gene deletion, homozygoteEffect Directly StudiedPatients with this genotype have reduced metabolism of codeine.Details
Cytochrome P450 2D6CYP2D6*3Not Available2549delAEffect Directly StudiedThe presence of this polymorphism in CYP2D6 results in non-functioning enzyme variant and may be associated with reduced drug mtabolism or reduced therapeutic response when treated with codeine.Details
Cytochrome P450 2D6CYP2D6*4Not AvailableA alleleEffect Directly StudiedThe presence of this polymorphism in CYP2D6 is associated with poor metabolism of codeine.Details
Cytochrome P450 2D6CYP2D6*5Not AvailableWhole-gene deletionEffect Directly StudiedThe presence of this polymorphism in CYP2D6 is associated with poor metabolism of codeine and lack of therapeutic response from codeine.Details
Cytochrome P450 2D6CYP2D6*6(-;T) / (-;-)1707delTEffect Directly StudiedThe presence of this polymorphism in CYP2D6 is associated with poor metabolism of codeine.Details
Cytochrome P450 2D6CYP2D6*7Not Available2935A>CEffect InferredPoor drug metabolizer. Lack of efficacy. For individual with two non-functional alleles, alternative drug recommended.Details
Cytochrome P450 2D6CYP2D6*8Not Available1758G>TEffect InferredPoor drug metabolizer. Lack of efficacy. For individual with two non-functional alleles, alternative drug recommended.Details
Cytochrome P450 2D6CYP2D6*11Not Available883G>CEffect InferredPoor drug metabolizer. Lack of efficacy. For individual with two non-functional alleles, alternative drug recommended.Details
Cytochrome P450 2D6CYP2D6*12Not Available124G>AEffect InferredPoor drug metabolizer. Lack of efficacy. For individual with two non-functional alleles, alternative drug recommended.Details
Cytochrome P450 2D6CYP2D6*13Not AvailableCYP2D7/2D6 hybrid gene structureEffect InferredPoor drug metabolizer. Lack of efficacy. For individual with two non-functional alleles, alternative drug recommended.Details
Cytochrome P450 2D6CYP2D6*14ANot Available1758G>AEffect InferredPoor drug metabolizer. Lack of efficacy. For individual with two non-functional alleles, alternative drug recommended.Details
Cytochrome P450 2D6CYP2D6*15Not Available137insT, 137_138insTEffect InferredPoor drug metabolizer. Lack of efficacy. For individual with two non-functional alleles, alternative drug recommended.Details
Cytochrome P450 2D6CYP2D6*19Not Available2539_2542delAACTEffect InferredPoor drug metabolizer. Lack of efficacy. For individual with two non-functional alleles, alternative drug recommended.Details
Cytochrome P450 2D6CYP2D6*20Not Available1973_1974insGEffect InferredPoor drug metabolizer. Lack of efficacy. For individual with two non-functional alleles, alternative drug recommended.Details
Cytochrome P450 2D6CYP2D6*21Not Available2573insCEffect InferredPoor drug metabolizer. Lack of efficacy. For individual with two non-functional alleles, alternative drug recommended.Details
Cytochrome P450 2D6CYP2D6*31Not Available-1770G>A / -1584C>G  … show all Effect InferredPoor drug metabolizer. Lack of efficacy. For individual with two non-functional alleles, alternative drug recommended.Details
Cytochrome P450 2D6CYP2D6*36Not Available100C>T / -1426C>T  … show all Effect InferredPoor drug metabolizer. Lack of efficacy. For individual with two non-functional alleles, alternative drug recommended.Details
Cytochrome P450 2D6CYP2D6*38Not Available2587_2590delGACTEffect InferredPoor drug metabolizer. Lack of efficacy. For individual with two non-functional alleles, alternative drug recommended.Details
Cytochrome P450 2D6CYP2D6*40Not Available1863_1864ins(TTT CGC CCC)2Effect InferredPoor drug metabolizer. Lack of efficacy. For individual with two non-functional alleles, alternative drug recommended.Details
Cytochrome P450 2D6CYP2D6*42Not Available3259_3260insGTEffect InferredPoor drug metabolizer. Lack of efficacy. For individual with two non-functional alleles, alternative drug recommended.Details
Cytochrome P450 2D6CYP2D6*44Not Available2950G>CEffect InferredPoor drug metabolizer. Lack of efficacy. For individual with two non-functional alleles, alternative drug recommended.Details
Cytochrome P450 2D6CYP2D6*47Not Available100C>T / -1426C>T  … show all Effect InferredPoor drug metabolizer. Lack of efficacy. For individual with two non-functional alleles, alternative drug recommended.Details
Cytochrome P450 2D6CYP2D6*51Not Available-1584C>G / -1235A>G  … show all Effect InferredPoor drug metabolizer. Lack of efficacy. For individual with two non-functional alleles, alternative drug recommended.Details
Cytochrome P450 2D6CYP2D6*56Not Available3201C>TEffect InferredPoor drug metabolizer. Lack of efficacy. For individual with two non-functional alleles, alternative drug recommended.Details
Cytochrome P450 2D6CYP2D6*57Not Available100C>T / 310G>T  … show all Effect InferredPoor drug metabolizer. Lack of efficacy. For individual with two non-functional alleles, alternative drug recommended.Details
Cytochrome P450 2D6CYP2D6*62Not Available4044C>TEffect InferredPoor drug metabolizer. Lack of efficacy. For individual with two non-functional alleles, alternative drug recommended.Details
Cytochrome P450 2D6CYP2D6*68ANot Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer. Lack of efficacy. For individual with two non-functional alleles, alternative drug recommended.Details
Cytochrome P450 2D6CYP2D6*68BNot AvailableSimilar but not identical switch region compared to CYP2D6*68A. Found in tandem arrangement with CYP2D6*4.Effect InferredPoor drug metabolizer. Lack of efficacy. For individual with two non-functional alleles, alternative drug recommended.Details
Cytochrome P450 2D6CYP2D6*69Not Available2988G>A / -1426C>T  … show all Effect InferredPoor drug metabolizer. Lack of efficacy. For individual with two non-functional alleles, alternative drug recommended.Details
Cytochrome P450 2D6CYP2D6*92Not Available1995delCEffect InferredPoor drug metabolizer. Lack of efficacy. For individual with two non-functional alleles, alternative drug recommended.Details
Cytochrome P450 2D6CYP2D6*100Not Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer. Lack of efficacy. For individual with two non-functional alleles, alternative drug recommended.Details
Cytochrome P450 2D6CYP2D6*101Not Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer. Lack of efficacy. For individual with two non-functional alleles, alternative drug recommended.Details
Cytochrome P450 2D6CYP2D6*1XNNot AvailableNormal allele duplicated.ADR InferredUltra-rapid drug metabolizer. Risk of toxicity, alternative drug recommended.Details
Cytochrome P450 2D6CYP2D6*2XNNot Available2850C>T / 4180G>C  … show all ADR InferredUltra-rapid drug metabolizer. Risk of toxicity, alternative drug recommended.Details
Cytochrome P450 2D6CYP2D6*3Not AvailableC alleleEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2D6CYP2D6*7Not Available2935A>CEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2D6CYP2D6*8Not Available1758G>TEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2D6CYP2D6*11Not Available883G>CEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2D6CYP2D6*12Not Available124G>AEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2D6CYP2D6*13Not AvailableCYP2D7/2D6 hybrid gene structureEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2D6CYP2D6*14ANot Available1758G>AEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2D6CYP2D6*15Not Available137insT, 137_138insTEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2D6CYP2D6*19Not Available2539_2542delAACTEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2D6CYP2D6*20Not Available1973_1974insGEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2D6CYP2D6*21Not Available2573insCEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2D6CYP2D6*31Not Available-1770G>A / -1584C>G  … show all Effect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2D6CYP2D6*36Not Available100C>T / -1426C>T  … show all Effect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2D6CYP2D6*38Not Available2587_2590delGACTEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2D6CYP2D6*40Not Available1863_1864ins(TTT CGC CCC)2Effect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2D6CYP2D6*42Not Available3259_3260insGTEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2D6CYP2D6*44Not Available2950G>CEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2D6CYP2D6*47Not Available100C>T / -1426C>T  … show all Effect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2D6CYP2D6*51Not Available-1584C>G / -1235A>G  … show all Effect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2D6CYP2D6*56Not Available3201C>TEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2D6CYP2D6*57Not Available100C>T / 310G>T  … show all Effect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2D6CYP2D6*62Not Available4044C>TEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2D6CYP2D6*68ANot Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2D6CYP2D6*68BNot AvailableSimilar but not identical switch region compared to CYP2D6*68A. Found in tandem arrangement with CYP2D6*4.Effect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2D6CYP2D6*69Not Available2988G>A / -1426C>T  … show all Effect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2D6CYP2D6*92Not Available1995delCEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2D6CYP2D6*100Not Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2D6CYP2D6*101Not Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2D6CYP2D6*3Not AvailableG alleleEffect Directly StudiedThe presence of this polymorphism in CYP2D6 results in non-functioning enzyme variant and may be associated with reduced therapeutic response when treated with codeine.Details
Cytochrome P450 2D6CYP2D6*4Not Available3877G>AEffect Directly StudiedThe presence of this polymorphism in CYP2D6 results in non-functioning enzyme variant and may be associated with reduced therapeutic response when treated with codeine.Details

Interactions

Drug Interactions
DrugInteractionDrug group
(2-benzhydryloxyethyl)diethyl-methylammonium iodideThe risk or severity of adverse effects can be increased when (2-benzhydryloxyethyl)diethyl-methylammonium iodide is combined with Codeine.Experimental
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Codeine.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamine2,5-Dimethoxy-4-ethylthioamphetamine may increase the analgesic activities of Codeine.Experimental
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may increase the analgesic activities of Codeine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Codeine.Experimental, Illicit
4-MethoxyamphetamineThe risk or severity of adverse effects can be increased when Codeine is combined with 4-Methoxyamphetamine.Experimental, Illicit
5-methoxy-N,N-dimethyltryptamineThe risk or severity of adverse effects can be increased when Codeine is combined with 5-methoxy-N,N-dimethyltryptamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Codeine is combined with 7-Nitroindazole.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe risk or severity of adverse effects can be increased when Codeine is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Experimental
AbirateroneThe serum concentration of Codeine can be increased when it is combined with Abiraterone.Approved
AcepromazineThe risk or severity of hypotension and central nervous system depression can be increased when Acepromazine is combined with Codeine.Approved, Vet Approved
AceprometazineThe risk or severity of hypotension and central nervous system depression can be increased when Aceprometazine is combined with Codeine.Approved
AcetazolamideThe therapeutic efficacy of Acetazolamide can be decreased when used in combination with Codeine.Approved, Vet Approved
AcetophenazineThe risk or severity of hypotension and central nervous system depression can be increased when Acetophenazine is combined with Codeine.Approved
Acetylglycinamide chloral hydrateThe risk or severity of adverse effects can be increased when Codeine is combined with Acetylglycinamide chloral hydrate.Experimental
AclidiniumThe risk or severity of adverse effects can be increased when Aclidinium is combined with Codeine.Approved
AdinazolamThe risk or severity of adverse effects can be increased when Codeine is combined with Adinazolam.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Codeine is combined with Adipiplon.Investigational
AgmatineThe risk or severity of adverse effects can be increased when Agmatine is combined with Codeine.Experimental, Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Codeine is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Codeine is combined with Alaproclate.Experimental
AlcuroniumThe risk or severity of adverse effects can be increased when Codeine is combined with Alcuronium.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Codeine is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Codeine is combined with Alfentanil.Approved, Illicit
AlimemazineThe risk or severity of hypotension and central nervous system depression can be increased when Alimemazine is combined with Codeine.Approved, Vet Approved
AllobarbitalThe risk or severity of adverse effects can be increased when Codeine is combined with Allobarbital.Experimental
AllopregnanoloneThe risk or severity of adverse effects can be increased when Codeine is combined with Allopregnanolone.Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Codeine.Approved, Investigational
AlosetronThe risk or severity of adverse effects can be increased when Codeine is combined with Alosetron.Approved, Withdrawn
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Codeine is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Codeine is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Codeine is combined with Alprazolam.Approved, Illicit, Investigational
AlprenololThe risk or severity of adverse effects can be increased when Codeine is combined with Alprenolol.Approved, Withdrawn
AlverineThe risk or severity of adverse effects can be increased when Codeine is combined with Alverine.Approved, Investigational
AlvimopanThe risk or severity of adverse effects can be increased when Codeine is combined with Alvimopan.Approved, Investigational
AmantadineThe risk or severity of adverse effects can be increased when Amantadine is combined with Codeine.Approved
AmikacinThe risk or severity of adverse effects can be increased when Codeine is combined with Amikacin.Approved, Investigational, Vet Approved
AmilorideThe therapeutic efficacy of Amiloride can be decreased when used in combination with Codeine.Approved
AmineptineThe risk or severity of adverse effects can be increased when Codeine is combined with Amineptine.Illicit, Withdrawn
AmiodaroneThe therapeutic efficacy of Codeine can be decreased when used in combination with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Codeine is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Codeine.Approved
AmitriptylinoxideThe risk or severity of adverse effects can be increased when Codeine is combined with Amitriptylinoxide.Approved, Investigational
Ammonium chlorideAmmonium chloride may increase the excretion rate of Codeine which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational, Vet Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Codeine is combined with Amobarbital.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Codeine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Codeine is combined with Amperozide.Experimental
AmphetamineAmphetamine may increase the analgesic activities of Codeine.Approved, Illicit, Investigational
AmprenavirThe metabolism of Codeine can be decreased when combined with Amprenavir.Approved, Investigational
AniracetamThe risk or severity of adverse effects can be increased when Codeine is combined with Aniracetam.Experimental
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Codeine.Approved
ApalutamideThe serum concentration of Codeine can be decreased when it is combined with Apalutamide.Approved, Investigational
APD791The risk or severity of adverse effects can be increased when Codeine is combined with APD791.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Codeine is combined with Apomorphine.Approved, Investigational
ApramycinThe risk or severity of adverse effects can be increased when Codeine is combined with Apramycin.Experimental, Vet Approved
AprepitantThe serum concentration of Codeine can be increased when it is combined with Aprepitant.Approved, Investigational
AprobarbitalThe risk or severity of adverse effects can be increased when Codeine is combined with Aprobarbital.Approved, Illicit
ApronalideThe risk or severity of adverse effects can be increased when Codeine is combined with Apronalide.Experimental
Arbaclofen PlacarbilThe risk or severity of adverse effects can be increased when Codeine is combined with Arbaclofen Placarbil.Investigational
ArbekacinThe risk or severity of adverse effects can be increased when Codeine is combined with Arbekacin.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Codeine.Approved, Investigational
Aripiprazole lauroxilThe risk or severity of adverse effects can be increased when Codeine is combined with Aripiprazole lauroxil.Approved, Investigational
AsenapineThe risk or severity of adverse effects can be increased when Codeine is combined with Asenapine.Approved
AsunaprevirThe therapeutic efficacy of Codeine can be decreased when used in combination with Asunaprevir.Approved, Investigational, Withdrawn
AtazanavirThe metabolism of Codeine can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe risk or severity of adverse effects can be increased when Codeine is combined with Atomoxetine.Approved
AtracuriumThe risk or severity of adverse effects can be increased when Codeine is combined with Atracurium.Approved, Experimental, Investigational
Atracurium besylateThe risk or severity of adverse effects can be increased when Codeine is combined with Atracurium besylate.Approved
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Codeine.Approved, Vet Approved
AzaperoneThe risk or severity of adverse effects can be increased when Codeine is combined with Azaperone.Investigational, Vet Approved
AZD-3043The risk or severity of adverse effects can be increased when Codeine is combined with AZD-3043.Investigational
AzelastineCodeine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzosemideThe therapeutic efficacy of Azosemide can be decreased when used in combination with Codeine.Investigational
BaclofenThe risk or severity of adverse effects can be increased when Codeine is combined with Baclofen.Approved
BarbexacloneThe risk or severity of adverse effects can be increased when Codeine is combined with Barbexaclone.Experimental
BarbitalThe risk or severity of adverse effects can be increased when Codeine is combined with Barbital.Illicit
Barbituric acid derivativeThe risk or severity of adverse effects can be increased when Barbituric acid derivative is combined with Codeine.Experimental, Illicit
BeclamideThe risk or severity of adverse effects can be increased when Codeine is combined with Beclamide.Experimental
BekanamycinThe risk or severity of adverse effects can be increased when Codeine is combined with Bekanamycin.Experimental
BenactyzineThe risk or severity of adverse effects can be increased when Codeine is combined with Benactyzine.Withdrawn
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Codeine.Approved
BenmoxinThe risk or severity of adverse effects can be increased when Codeine is combined with Benmoxin.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Codeine is combined with Benperidol.Approved, Investigational
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Codeine.Approved
BenziloneThe risk or severity of adverse effects can be increased when Benzilone is combined with Codeine.Experimental
BenzoctamineThe risk or severity of adverse effects can be increased when Codeine is combined with Benzoctamine.Approved
BenzphetamineThe risk or severity of serotonin syndrome can be increased when Codeine is combined with Benzphetamine.Approved, Illicit
BenzquinamideThe risk or severity of adverse effects can be increased when Benzquinamide is combined with Codeine.Withdrawn
BenzthiazideThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Codeine.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Codeine is combined with Benzyl alcohol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Codeine.Experimental
BezitramideThe risk or severity of adverse effects can be increased when Codeine is combined with Bezitramide.Experimental, Illicit, Withdrawn
BifemelaneThe risk or severity of adverse effects can be increased when Bifemelane is combined with Codeine.Experimental
BifeprunoxThe risk or severity of adverse effects can be increased when Codeine is combined with Bifeprunox.Investigational
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Codeine.Approved, Investigational
BisacodylThe therapeutic efficacy of Bisacodyl can be decreased when used in combination with Codeine.Approved
BisoxatinThe therapeutic efficacy of Bisoxatin can be decreased when used in combination with Codeine.Approved
BL-1020The risk or severity of hypotension and central nervous system depression can be increased when BL-1020 is combined with Codeine.Investigational
BlonanserinThe risk or severity of adverse effects can be increased when Codeine is combined with Blonanserin.Approved, Investigational
BoceprevirThe metabolism of Codeine can be decreased when combined with Boceprevir.Approved, Withdrawn
BornaprineThe risk or severity of adverse effects can be increased when Bornaprine is combined with Codeine.Experimental
BosentanThe serum concentration of Codeine can be decreased when it is combined with Bosentan.Approved, Investigational
Botulinum Toxin Type AThe risk or severity of adverse effects can be increased when Codeine is combined with Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BThe risk or severity of adverse effects can be increased when Codeine is combined with Botulinum Toxin Type B.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Codeine is combined with Brexpiprazole.Approved, Investigational
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Codeine.Approved
BrinzolamideThe therapeutic efficacy of Brinzolamide can be decreased when used in combination with Codeine.Approved
BrivaracetamThe risk or severity of adverse effects can be increased when Codeine is combined with Brivaracetam.Approved, Investigational
BrofaromineThe risk or severity of adverse effects can be increased when Codeine is combined with Brofaromine.Experimental
BromazepamThe risk or severity of adverse effects can be increased when Codeine is combined with Bromazepam.Approved, Illicit, Investigational
BromisovalThe risk or severity of adverse effects can be increased when Codeine is combined with Bromisoval.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Codeine is combined with Bromocriptine.Approved, Investigational
BromotheophyllineThe therapeutic efficacy of Bromotheophylline can be decreased when used in combination with Codeine.Approved
BromperidolThe risk or severity of adverse effects can be increased when Codeine is combined with Bromperidol.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Codeine is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Codeine is combined with Brotizolam.Approved, Investigational, Withdrawn
BuclizineThe risk or severity of adverse effects can be increased when Buclizine is combined with Codeine.Approved
BufotenineThe risk or severity of adverse effects can be increased when Codeine is combined with Bufotenine.Experimental, Illicit
BumetanideThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Codeine.Approved
BuprenorphineCodeine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe therapeutic efficacy of Codeine can be decreased when used in combination with Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Codeine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Codeine.Approved, Illicit
ButalbitalThe risk or severity of adverse effects can be increased when Codeine is combined with Butalbital.Approved, Illicit
ButaperazineThe risk or severity of hypotension and central nervous system depression can be increased when Butaperazine is combined with Codeine.Experimental
ButethalThe risk or severity of adverse effects can be increased when Codeine is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Codeine.Approved, Illicit, Vet Approved
ButriptylineThe risk or severity of adverse effects can be increased when Codeine is combined with Butriptyline.Approved
ButylscopolamineThe risk or severity of adverse effects can be increased when Butylscopolamine is combined with Codeine.Approved, Investigational, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Codeine is combined with Cabergoline.Approved
CamazepamThe risk or severity of adverse effects can be increased when Codeine is combined with Camazepam.Approved, Illicit
CamylofinThe risk or severity of adverse effects can be increased when Camylofin is combined with Codeine.Experimental
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Codeine.Approved
CannabidiolThe risk or severity of adverse effects can be increased when Codeine is combined with Cannabidiol.Approved, Investigational
CannabidivarinThe risk or severity of adverse effects can be increased when Codeine is combined with Cannabidivarin.Investigational
Canrenoic acidThe therapeutic efficacy of Canrenoic acid can be decreased when used in combination with Codeine.Approved, Withdrawn
CanrenoneThe therapeutic efficacy of Canrenone can be decreased when used in combination with Codeine.Investigational
CapreomycinThe risk or severity of adverse effects can be increased when Codeine is combined with Capreomycin.Approved
CaptodiameThe risk or severity of adverse effects can be increased when Codeine is combined with Captodiame.Approved, Investigational
CarbamazepineThe serum concentration of Codeine can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Codeine is combined with Carbinoxamine.Approved
CarboxymethylcelluloseThe therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Codeine.Approved, Investigational
CarbromalThe risk or severity of adverse effects can be increased when Codeine is combined with Carbromal.Experimental
CarfentanilThe risk or severity of adverse effects can be increased when Codeine is combined with Carfentanil.Illicit, Investigational, Vet Approved
CariprazineThe risk or severity of adverse effects can be increased when Codeine is combined with Cariprazine.Approved, Investigational
CarisbamateThe risk or severity of adverse effects can be increased when Codeine is combined with Carisbamate.Investigational
CarisoprodolThe risk or severity of adverse effects can be increased when Codeine is combined with Carisoprodol.Approved
CaroxazoneThe risk or severity of adverse effects can be increased when Codeine is combined with Caroxazone.Withdrawn
Castor oilThe therapeutic efficacy of Castor oil can be decreased when used in combination with Codeine.Approved, Investigational, Nutraceutical, Vet Approved
CathinoneThe risk or severity of adverse effects can be increased when Codeine is combined with Cathinone.Illicit
CeritinibThe serum concentration of Codeine can be increased when it is combined with Ceritinib.Approved
CerlapirdineThe risk or severity of adverse effects can be increased when Codeine is combined with Cerlapirdine.Investigational
CetirizineThe risk or severity of adverse effects can be increased when Codeine is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Codeine is combined with Chloral hydrate.Approved, Illicit, Investigational, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Codeine is combined with Chlordiazepoxide.Approved, Illicit, Investigational
ChlormezanoneThe risk or severity of adverse effects can be increased when Codeine is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Codeine.Approved
ChloroquineThe therapeutic efficacy of Codeine can be decreased when used in combination with Chloroquine.Approved, Investigational, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Codeine.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Codeine.Approved
ChlorphenesinThe risk or severity of adverse effects can be increased when Codeine is combined with Chlorphenesin.Approved, Vet Approved, Withdrawn
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Codeine.Withdrawn
ChlorphentermineChlorphentermine may increase the analgesic activities of Codeine.Illicit, Withdrawn
ChlorproethazineThe risk or severity of hypotension and central nervous system depression can be increased when Chlorproethazine is combined with Codeine.Experimental
ChlorpromazineThe therapeutic efficacy of Codeine can be decreased when used in combination with Chlorpromazine.Approved, Investigational, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Codeine is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlortetracyclineThe risk or severity of adverse effects can be increased when Codeine is combined with Chlortetracycline.Approved, Investigational, Vet Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Codeine.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Codeine is combined with Chlorzoxazone.Approved
CholecalciferolThe therapeutic efficacy of Codeine can be decreased when used in combination with Cholecalciferol.Approved, Nutraceutical
CicletanineThe therapeutic efficacy of Cicletanine can be decreased when used in combination with Codeine.Investigational
CilansetronThe risk or severity of adverse effects can be increased when Codeine is combined with Cilansetron.Investigational
CimetidineThe therapeutic efficacy of Codeine can be decreased when used in combination with Cimetidine.Approved, Investigational
CinacalcetThe therapeutic efficacy of Codeine can be decreased when used in combination with Cinacalcet.Approved
CinitaprideThe risk or severity of adverse effects can be increased when Codeine is combined with Cinitapride.Approved, Investigational
CinolazepamThe risk or severity of adverse effects can be increased when Codeine is combined with Cinolazepam.Approved
CisaprideThe risk or severity of adverse effects can be increased when Codeine is combined with Cisapride.Approved, Investigational, Withdrawn
CisatracuriumThe risk or severity of adverse effects can be increased when Codeine is combined with Cisatracurium.Approved
CitalopramThe risk or severity of adverse effects can be increased when Citalopram is combined with Codeine.Approved
ClarithromycinThe metabolism of Codeine can be decreased when combined with Clarithromycin.Approved
ClemastineThe therapeutic efficacy of Codeine can be decreased when used in combination with Clemastine.Approved, Investigational
ClidiniumThe risk or severity of adverse effects can be increased when Codeine is combined with Clidinium.Approved
ClindamycinThe risk or severity of adverse effects can be increased when Codeine is combined with Clindamycin.Approved, Vet Approved
ClobazamThe therapeutic efficacy of Codeine can be decreased when used in combination with Clobazam.Approved, Illicit
ClofenamideThe therapeutic efficacy of Clofenamide can be decreased when used in combination with Codeine.Experimental
clomethiazoleThe risk or severity of adverse effects can be increased when Codeine is combined with clomethiazole.Investigational
ClomipramineThe therapeutic efficacy of Codeine can be decreased when used in combination with Clomipramine.Approved, Investigational, Vet Approved
ClomocyclineThe risk or severity of adverse effects can be increased when Codeine is combined with Clomocycline.Approved
ClonazepamThe risk or severity of adverse effects can be increased when Codeine is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Codeine is combined with Clonidine.Approved
ClopamideThe therapeutic efficacy of Clopamide can be decreased when used in combination with Codeine.Experimental
ClopenthixolThe risk or severity of adverse effects can be increased when Codeine is combined with Clopenthixol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Codeine is combined with Clorazepate.Approved, Illicit
ClorexoloneThe therapeutic efficacy of Clorexolone can be decreased when used in combination with Codeine.Experimental
ClothiapineThe risk or severity of adverse effects can be increased when Codeine is combined with Clothiapine.Experimental
ClotiazepamThe risk or severity of adverse effects can be increased when Codeine is combined with Clotiazepam.Approved, Illicit
ClotrimazoleThe metabolism of Codeine can be decreased when combined with Clotrimazole.Approved, Vet Approved
CloxazolamThe risk or severity of adverse effects can be increased when Codeine is combined with Cloxazolam.Approved, Investigational
ClozapineThe risk or severity of adverse effects can be increased when Codeine is combined with Clozapine.Approved
CobicistatThe serum concentration of Codeine can be increased when it is combined with Cobicistat.Approved
CocaineThe therapeutic efficacy of Codeine can be decreased when used in combination with Cocaine.Approved, Illicit
ColistimethateThe risk or severity of adverse effects can be increased when Codeine is combined with Colistimethate.Approved, Vet Approved
ColistinThe risk or severity of adverse effects can be increased when Codeine is combined with Colistin.Approved
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Codeine.Approved, Investigational
CrizotinibThe metabolism of Codeine can be decreased when combined with Crizotinib.Approved
CurcuminThe therapeutic efficacy of Codeine can be decreased when used in combination with Curcumin.Approved, Investigational
CyamemazineThe risk or severity of hypotension and central nervous system depression can be increased when Cyamemazine is combined with Codeine.Approved
CyclizineThe risk or severity of adverse effects can be increased when Codeine is combined with Cyclizine.Approved
CyclobarbitalThe risk or severity of adverse effects can be increased when Codeine is combined with Cyclobarbital.Experimental
CyclobenzaprineThe risk or severity of adverse effects can be increased when Codeine is combined with Cyclobenzaprine.Approved
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Codeine.Experimental
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Codeine.Approved
CyclopropaneThe risk or severity of adverse effects can be increased when Codeine is combined with Cyclopropane.Experimental
CyclosporineThe risk or severity of adverse effects can be increased when Codeine is combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideThe therapeutic efficacy of Cyclothiazide can be decreased when used in combination with Codeine.Approved
CycrimineThe risk or severity of adverse effects can be increased when Cycrimine is combined with Codeine.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Codeine is combined with Cyproheptadine.Approved
DabrafenibThe serum concentration of Codeine can be decreased when it is combined with Dabrafenib.Approved, Investigational
DanazolThe metabolism of Codeine can be decreased when combined with Danazol.Approved
DanthronThe therapeutic efficacy of Danthron can be decreased when used in combination with Codeine.Approved, Investigational, Withdrawn
DantroleneThe risk or severity of adverse effects can be increased when Codeine is combined with Dantrolene.Approved, Investigational
DapagliflozinThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Codeine.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Codeine is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Codeine.Investigational
DarifenacinThe therapeutic efficacy of Codeine can be decreased when used in combination with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Codeine can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Codeine can be increased when it is combined with Dasatinib.Approved, Investigational
DeanolThe risk or severity of adverse effects can be increased when Codeine is combined with Deanol.Experimental
DecamethoniumThe risk or severity of adverse effects can be increased when Codeine is combined with Decamethonium.Approved
DeferasiroxThe serum concentration of Codeine can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe therapeutic efficacy of Codeine can be decreased when used in combination with Delavirdine.Approved
DelorazepamThe risk or severity of adverse effects can be increased when Codeine is combined with Delorazepam.Approved, Illicit, Investigational
DemeclocyclineThe risk or severity of adverse effects can be increased when Codeine is combined with Demeclocycline.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Codeine is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Codeine is combined with Desflurane.Approved
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Codeine.Approved, Investigational
DesloratadineThe risk or severity of adverse effects can be increased when Codeine is combined with Desloratadine.Approved, Investigational
DesmopressinThe risk or severity of hyponatremia can be increased when Codeine is combined with Desmopressin.Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Codeine.Approved, Investigational
DetomidineThe risk or severity of adverse effects can be increased when Codeine is combined with Detomidine.Vet Approved
DexamethasoneThe serum concentration of Codeine can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Codeine is combined with Dexbrompheniramine.Approved
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Codeine.Withdrawn
DexmedetomidineThe risk or severity of adverse effects can be increased when Codeine is combined with Dexmedetomidine.Approved, Vet Approved
DexmethylphenidateThe risk or severity of adverse effects can be increased when Codeine is combined with Dexmethylphenidate.Approved, Investigational
DextofisopamThe risk or severity of adverse effects can be increased when Codeine is combined with Dextofisopam.Investigational
DextroamphetamineDextroamphetamine may increase the analgesic activities of Codeine.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Codeine.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Codeine.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Codeine.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Codeine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Codeine is combined with Diazepam.Approved, Illicit, Investigational, Vet Approved
DibekacinThe risk or severity of adverse effects can be increased when Codeine is combined with Dibekacin.Experimental
DibenzepinThe risk or severity of adverse effects can be increased when Codeine is combined with Dibenzepin.Experimental
DichloralphenazoneThe risk or severity of adverse effects can be increased when Codeine is combined with Dichloralphenazone.Approved, Illicit
DiclofenamideThe therapeutic efficacy of Diclofenamide can be decreased when used in combination with Codeine.Approved, Investigational
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Codeine.Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Codeine is combined with Diethyl ether.Experimental
DiethylpropionDiethylpropion may increase the analgesic activities of Codeine.Approved, Illicit
DifemerineThe risk or severity of adverse effects can be increased when Difemerine is combined with Codeine.Experimental
DifenoxinThe risk or severity of adverse effects can be increased when Codeine is combined with Difenoxin.Approved, Illicit
DihexyverineThe risk or severity of adverse effects can be increased when Dihexyverine is combined with Codeine.Experimental
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Codeine.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Codeine.Approved, Investigational
DihydroetorphineThe risk or severity of adverse effects can be increased when Codeine is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Codeine is combined with Dihydromorphine.Experimental, Illicit
DihydrostreptomycinThe risk or severity of adverse effects can be increased when Codeine is combined with Dihydrostreptomycin.Investigational, Vet Approved
DiltiazemThe metabolism of Codeine can be decreased when combined with Diltiazem.Approved, Investigational
DimenhydrinateThe risk or severity of adverse effects can be increased when Codeine is combined with Dimenhydrinate.Approved
DimetacrineThe risk or severity of adverse effects can be increased when Codeine is combined with Dimetacrine.Approved, Withdrawn
DimethyltryptamineThe risk or severity of adverse effects can be increased when Codeine is combined with Dimethyltryptamine.Experimental, Illicit
DimetindeneThe risk or severity of adverse effects can be increased when Dimetindene is combined with Codeine.Approved, Investigational
DiphemanilThe risk or severity of adverse effects can be increased when Diphemanil is combined with Codeine.Experimental
Diphemanil MethylsulfateThe risk or severity of adverse effects can be increased when Diphemanil Methylsulfate is combined with Codeine.Approved, Vet Approved, Withdrawn
DiphenhydramineThe therapeutic efficacy of Codeine can be decreased when used in combination with Diphenhydramine.Approved, Investigational
DiphenidolThe risk or severity of adverse effects can be increased when Diphenidol is combined with Codeine.Approved, Investigational, Withdrawn
DiphenoxylateThe risk or severity of adverse effects can be increased when Codeine is combined with Diphenoxylate.Approved, Illicit
DisopyramideThe risk or severity of adverse effects can be increased when Disopyramide is combined with Codeine.Approved
DixyrazineThe risk or severity of hypotension and central nervous system depression can be increased when Dixyrazine is combined with Codeine.Experimental
DocusateThe therapeutic efficacy of Docusate can be decreased when used in combination with Codeine.Approved
DolasetronThe risk or severity of adverse effects can be increased when Codeine is combined with Dolasetron.Approved, Investigational
Domoic AcidThe risk or severity of adverse effects can be increased when Codeine is combined with Domoic Acid.Experimental
DonepezilThe risk or severity of adverse effects can be increased when Codeine is combined with Donepezil.Approved
DopamineThe risk or severity of adverse effects can be increased when Codeine is combined with Dopamine.Approved
DoramectinThe risk or severity of adverse effects can be increased when Codeine is combined with Doramectin.Vet Approved
DorzolamideThe therapeutic efficacy of Dorzolamide can be decreased when used in combination with Codeine.Approved
DosulepinThe risk or severity of adverse effects can be increased when Codeine is combined with Dosulepin.Approved
DotarizineThe risk or severity of adverse effects can be increased when Codeine is combined with Dotarizine.Investigational
DoxacuriumThe risk or severity of adverse effects can be increased when Codeine is combined with Doxacurium.Approved
DoxefazepamThe risk or severity of adverse effects can be increased when Codeine is combined with Doxefazepam.Experimental
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Codeine.Approved, Investigational
DoxycyclineThe metabolism of Codeine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Codeine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Codeine is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Codeine.Approved, Illicit
DronedaroneThe therapeutic efficacy of Codeine can be decreased when used in combination with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Codeine.Approved, Vet Approved
DrospirenoneThe therapeutic efficacy of Drospirenone can be decreased when used in combination with Codeine.Approved
DrotebanolThe risk or severity of adverse effects can be increased when Codeine is combined with Drotebanol.Experimental, Illicit
DuloxetineThe therapeutic efficacy of Codeine can be decreased when used in combination with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Codeine is combined with Dyclonine.Approved
EcopipamThe risk or severity of adverse effects can be increased when Codeine is combined with Ecopipam.Investigational
EdivoxetineThe risk or severity of adverse effects can be increased when Codeine is combined with Edivoxetine.Investigational
EfavirenzThe serum concentration of Codeine can be decreased when it is combined with Efavirenz.Approved, Investigational
EfonidipineThe therapeutic efficacy of Efonidipine can be decreased when used in combination with Codeine.Approved, Investigational
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Codeine.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Codeine is combined with Eltanolone.Investigational
EltoprazineThe risk or severity of adverse effects can be increased when Codeine is combined with Eltoprazine.Investigational
EluxadolineThe risk or severity of adverse effects can be increased when Codeine is combined with Eluxadoline.Approved, Investigational
EmeproniumThe risk or severity of adverse effects can be increased when Codeine is combined with Emepronium.Experimental
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Codeine.Approved
EmylcamateThe risk or severity of adverse effects can be increased when Codeine is combined with Emylcamate.Experimental
EnfluraneThe risk or severity of adverse effects can be increased when Codeine is combined with Enflurane.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Codeine is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Codeine can be decreased when it is combined with Enzalutamide.Approved
EperisoneThe risk or severity of adverse effects can be increased when Codeine is combined with Eperisone.Approved, Investigational
EpinastineThe risk or severity of adverse effects can be increased when Codeine is combined with Epinastine.Approved, Investigational
EpitizideThe therapeutic efficacy of Epitizide can be decreased when used in combination with Codeine.Experimental
EplerenoneThe therapeutic efficacy of Eplerenone can be decreased when used in combination with Codeine.Approved
EplivanserinThe risk or severity of adverse effects can be increased when Codeine is combined with Eplivanserin.Investigational
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Codeine is combined with Ergoloid mesylate.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Codeine is combined with Ergonovine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Codeine is combined with Ergotamine.Approved
ErythromycinThe metabolism of Codeine can be decreased when combined with Erythromycin.Approved, Investigational, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Codeine.Approved, Investigational
Eslicarbazepine acetateThe risk or severity of adverse effects can be increased when Codeine is combined with Eslicarbazepine acetate.Approved
EsmirtazapineThe risk or severity of adverse effects can be increased when Codeine is combined with Esmirtazapine.Investigational
EsreboxetineThe risk or severity of adverse effects can be increased when Codeine is combined with Esreboxetine.Investigational
EstazolamThe risk or severity of adverse effects can be increased when Codeine is combined with Estazolam.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Codeine is combined with Eszopiclone.Approved, Investigational
Etacrynic acidThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Codeine.Approved, Investigational
EtanautineThe risk or severity of adverse effects can be increased when Etanautine is combined with Codeine.Experimental
EthadioneThe risk or severity of adverse effects can be increased when Codeine is combined with Ethadione.Experimental
EthanolCodeine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Codeine is combined with Ethchlorvynol.Approved, Illicit, Withdrawn
Ethinyl EstradiolThe serum concentration of Codeine can be decreased when it is combined with Ethinyl Estradiol.Approved
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Codeine.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Codeine is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Codeine is combined with Ethotoin.Approved
EthoxzolamideThe therapeutic efficacy of Ethoxzolamide can be decreased when used in combination with Codeine.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Codeine is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Codeine is combined with Ethyl chloride.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Codeine is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Codeine is combined with Ethylmorphine.Approved, Illicit
EtifoxineThe risk or severity of adverse effects can be increased when Codeine is combined with Etifoxine.Investigational, Withdrawn
EtiracetamThe risk or severity of adverse effects can be increased when Codeine is combined with Etiracetam.Investigational
EtizolamThe risk or severity of adverse effects can be increased when Codeine is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Codeine is combined with Etomidate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Codeine is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Codeine is combined with Etorphine.Illicit, Vet Approved
EtravirineThe serum concentration of Codeine can be decreased when it is combined with Etravirine.Approved
EtybenzatropineThe risk or severity of adverse effects can be increased when Etybenzatropine is combined with Codeine.Experimental
EzogabineThe risk or severity of adverse effects can be increased when Codeine is combined with Ezogabine.Approved, Investigational
FabomotizoleThe risk or severity of adverse effects can be increased when Codeine is combined with Fabomotizole.Experimental
Fazadinium bromideThe risk or severity of adverse effects can be increased when Codeine is combined with Fazadinium bromide.Experimental
FebarbamateThe risk or severity of adverse effects can be increased when Codeine is combined with Febarbamate.Experimental
FelbamateThe risk or severity of adverse effects can be increased when Codeine is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Codeine is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenfluramineThe risk or severity of adverse effects can be increased when Codeine is combined with Fenfluramine.Approved, Illicit, Investigational, Withdrawn
FenpiveriniumThe risk or severity of adverse effects can be increased when Fenpiverinium is combined with Codeine.Experimental
FenquizoneThe therapeutic efficacy of Fenquizone can be decreased when used in combination with Codeine.Experimental
FentanylThe risk or severity of serotonin syndrome can be increased when Fentanyl is combined with Codeine.Approved, Illicit, Investigational, Vet Approved
FenyramidolThe risk or severity of adverse effects can be increased when Codeine is combined with Fenyramidol.Experimental
FesoterodineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Codeine.Approved
FexofenadineThe risk or severity of adverse effects can be increased when Codeine is combined with Fexofenadine.Approved, Investigational
FlavoxateThe risk or severity of adverse effects can be increased when Flavoxate is combined with Codeine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Codeine is combined with Flibanserin.Approved, Investigational
FluanisoneThe risk or severity of adverse effects can be increased when Codeine is combined with Fluanisone.Experimental
FluconazoleThe metabolism of Codeine can be decreased when combined with Fluconazole.Approved, Investigational
FludiazepamThe risk or severity of adverse effects can be increased when Codeine is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Codeine is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Codeine is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe therapeutic efficacy of Codeine can be decreased when used in combination with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Codeine is combined with Flupentixol.Approved, Investigational, Withdrawn
FluphenazineThe risk or severity of hypotension and central nervous system depression can be increased when Fluphenazine is combined with Codeine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Codeine is combined with Flurazepam.Approved, Illicit, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Codeine is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Codeine is combined with Fluticasone propionate.Approved
FluvoxamineThe therapeutic efficacy of Codeine can be decreased when used in combination with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Codeine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Codeine can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Codeine can be increased when combined with Fosphenytoin.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Codeine is combined with Fospropofol.Approved, Illicit, Investigational
FramycetinThe risk or severity of adverse effects can be increased when Codeine is combined with Framycetin.Approved
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Codeine.Approved, Investigational
FurazolidoneThe risk or severity of adverse effects can be increased when Codeine is combined with Furazolidone.Approved, Investigational, Vet Approved
FurosemideThe therapeutic efficacy of Furosemide can be decreased when used in combination with Codeine.Approved, Vet Approved
Fusidic AcidThe serum concentration of Codeine can be increased when it is combined with Fusidic Acid.Approved, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Codeine is combined with Gabapentin.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Codeine is combined with Gabapentin Enacarbil.Approved, Investigational
GaboxadolThe risk or severity of adverse effects can be increased when Codeine is combined with Gaboxadol.Investigational
GallamineThe risk or severity of adverse effects can be increased when Codeine is combined with Gallamine.Experimental
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Codeine is combined with Gallamine Triethiodide.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Codeine is combined with Gamma Hydroxybutyric Acid.Approved, Illicit, Investigational
Gantacurium ChlorideThe risk or severity of adverse effects can be increased when Codeine is combined with Gantacurium Chloride.Investigational
GedocarnilThe risk or severity of adverse effects can be increased when Codeine is combined with Gedocarnil.Experimental
GeneticinThe risk or severity of adverse effects can be increased when Codeine is combined with Geneticin.Experimental
GentamicinThe risk or severity of adverse effects can be increased when Codeine is combined with Gentamicin.Approved, Vet Approved
GENTAMICIN C1AThe risk or severity of adverse effects can be increased when Codeine is combined with GENTAMICIN C1A.Experimental
GepefrineGepefrine may increase the analgesic activities of Codeine.Experimental
GepironeThe risk or severity of adverse effects can be increased when Codeine is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Codeine is combined with Glutethimide.Approved, Illicit
GlycerinThe therapeutic efficacy of Glycerin can be decreased when used in combination with Codeine.Approved, Investigational
Glycerol PhenylbutyrateThe therapeutic efficacy of Codeine can be decreased when used in combination with Glycerol Phenylbutyrate.Approved
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Codeine.Approved, Investigational, Vet Approved
GranisetronThe risk or severity of adverse effects can be increased when Granisetron is combined with Codeine.Approved, Investigational
GuanfacineThe risk or severity of adverse effects can be increased when Codeine is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Codeine is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe therapeutic efficacy of Codeine can be decreased when used in combination with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Codeine is combined with Halothane.Approved, Vet Approved
HarmalineThe risk or severity of adverse effects can be increased when Codeine is combined with Harmaline.Experimental
HeptabarbitalThe risk or severity of adverse effects can be increased when Codeine is combined with Heptabarbital.Approved
HeroinThe risk or severity of adverse effects can be increased when Codeine is combined with Heroin.Approved, Illicit, Investigational
HexafluroniumThe risk or severity of adverse effects can be increased when Codeine is combined with Hexafluronium.Approved
HexamethoniumThe risk or severity of adverse effects can be increased when Codeine is combined with Hexamethonium.Experimental
HexapropymateThe risk or severity of adverse effects can be increased when Codeine is combined with Hexapropymate.Experimental
HexobarbitalThe risk or severity of adverse effects can be increased when Codeine is combined with Hexobarbital.Approved
HexocycliumThe risk or severity of adverse effects can be increased when Hexocyclium is combined with Codeine.Approved
HomatropineThe risk or severity of adverse effects can be increased when Homatropine is combined with Codeine.Approved
Homatropine MethylbromideThe risk or severity of adverse effects can be increased when Homatropine Methylbromide is combined with Codeine.Approved
HydracarbazineThe risk or severity of adverse effects can be increased when Codeine is combined with Hydracarbazine.Experimental
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Codeine.Approved, Vet Approved
HydrocodoneCodeine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Codeine.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Codeine.Approved, Illicit
HydroxyamphetamineHydroxyamphetamine may increase the analgesic activities of Codeine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Codeine.Approved
Hygromycin BThe risk or severity of adverse effects can be increased when Codeine is combined with Hygromycin B.Vet Approved
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Codeine.Approved
HypericinThe risk or severity of adverse effects can be increased when Codeine is combined with Hypericin.Investigational
IbopamineThe therapeutic efficacy of Ibopamine can be decreased when used in combination with Codeine.Experimental
IdalopirdineThe risk or severity of adverse effects can be increased when Codeine is combined with Idalopirdine.Investigational
IdelalisibThe metabolism of Codeine can be decreased when combined with Idelalisib.Approved
IfenprodilThe risk or severity of adverse effects can be increased when Codeine is combined with Ifenprodil.Approved, Investigational, Withdrawn
IferanserinThe risk or severity of adverse effects can be increased when Codeine is combined with Iferanserin.Investigational
IloperidoneThe risk or severity of adverse effects can be increased when Codeine is combined with Iloperidone.Approved
ImagabalinThe risk or severity of adverse effects can be increased when Codeine is combined with Imagabalin.Investigational
ImatinibThe metabolism of Codeine can be decreased when combined with Imatinib.Approved
ImidafenacinThe risk or severity of adverse effects can be increased when Imidafenacin is combined with Codeine.Approved, Investigational
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Codeine.Approved
Imipramine oxideThe risk or severity of adverse effects can be increased when Codeine is combined with Imipramine oxide.Experimental
IndalpineThe risk or severity of adverse effects can be increased when Codeine is combined with Indalpine.Investigational, Withdrawn
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Codeine.Approved
IndinavirThe metabolism of Codeine can be decreased when combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Codeine is combined with Indiplon.Investigational
Iofetamine I-123Iofetamine I-123 may increase the analgesic activities of Codeine.Approved
IpratropiumThe risk or severity of adverse effects can be increased when Ipratropium is combined with Codeine.Approved
IprazochromeThe risk or severity of adverse effects can be increased when Codeine is combined with Iprazochrome.Experimental
IprindoleThe risk or severity of adverse effects can be increased when Codeine is combined with Iprindole.Experimental
IproclozideThe risk or severity of adverse effects can be increased when Codeine is combined with Iproclozide.Withdrawn
IproniazidThe risk or severity of adverse effects can be increased when Codeine is combined with Iproniazid.Withdrawn
IsavuconazoleThe serum concentration of Codeine can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe metabolism of Codeine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsepamicinThe risk or severity of adverse effects can be increased when Codeine is combined with Isepamicin.Experimental
IsocarboxazidThe risk or severity of adverse effects can be increased when Codeine is combined with Isocarboxazid.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Codeine is combined with Isoflurane.Approved, Vet Approved
IsoniazidThe therapeutic efficacy of Codeine can be decreased when used in combination with Isoniazid.Approved, Investigational
IsopropamideThe risk or severity of adverse effects can be increased when Isopropamide is combined with Codeine.Approved, Vet Approved
IsosorbideThe therapeutic efficacy of Isosorbide can be decreased when used in combination with Codeine.Approved, Investigational
ItraconazoleThe metabolism of Codeine can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Codeine can be increased when it is combined with Ivacaftor.Approved
KanamycinThe risk or severity of adverse effects can be increased when Codeine is combined with Kanamycin.Approved, Investigational, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Codeine is combined with Ketamine.Approved, Vet Approved
KetanserinThe risk or severity of adverse effects can be increased when Codeine is combined with Ketanserin.Investigational
KetazolamThe risk or severity of adverse effects can be increased when Codeine is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Codeine.Approved, Investigational
KetoconazoleThe metabolism of Codeine can be decreased when combined with Ketoconazole.Approved, Investigational
L-TryptophanThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Codeine.Approved, Nutraceutical, Withdrawn
LacosamideThe risk or severity of adverse effects can be increased when Codeine is combined with Lacosamide.Approved
LactitolThe therapeutic efficacy of Lactitol can be decreased when used in combination with Codeine.Investigational
LactuloseThe therapeutic efficacy of Lactulose can be decreased when used in combination with Codeine.Approved
LamotrigineThe serum concentration of Codeine can be decreased when it is combined with Lamotrigine.Approved, Investigational
LanicemineThe risk or severity of adverse effects can be increased when Codeine is combined with Lanicemine.Investigational
LasmiditanThe risk or severity of adverse effects can be increased when Codeine is combined with Lasmiditan.Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Codeine is combined with Levetiracetam.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Codeine is combined with Levocabastine.Approved, Investigational
LevocetirizineThe risk or severity of adverse effects can be increased when Codeine is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Codeine.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Codeine is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Codeine.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Codeine.Approved
LinaclotideThe therapeutic efficacy of Linaclotide can be decreased when used in combination with Codeine.Approved
LincomycinThe risk or severity of adverse effects can be increased when Codeine is combined with Lincomycin.Approved, Vet Approved
LinezolidThe risk or severity of adverse effects can be increased when Codeine is combined with Linezolid.Approved, Investigational
LisdexamfetamineLisdexamfetamine may increase the analgesic activities of Codeine.Approved, Investigational
LisurideThe risk or severity of adverse effects can be increased when Codeine is combined with Lisuride.Approved, Investigational
Lithium carbonateThe risk or severity of adverse effects can be increased when Codeine is combined with Lithium carbonate.Approved
Lithium cationThe risk or severity of adverse effects can be increased when Lithium cation is combined with Codeine.Experimental
LofentanilThe risk or severity of adverse effects can be increased when Codeine is combined with Lofentanil.Illicit
LofepramineThe risk or severity of adverse effects can be increased when Codeine is combined with Lofepramine.Experimental
LofexidineThe therapeutic efficacy of Codeine can be increased when used in combination with Lofexidine.Approved, Investigational
LopinavirThe therapeutic efficacy of Codeine can be decreased when used in combination with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Codeine is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Codeine is combined with Loratadine.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Codeine.Approved
LorcaserinThe therapeutic efficacy of Codeine can be decreased when used in combination with Lorcaserin.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Codeine is combined with Lormetazepam.Approved
LorpiprazoleThe serum concentration of Codeine can be increased when it is combined with Lorpiprazole.Approved
LortalamineThe risk or severity of adverse effects can be increased when Codeine is combined with Lortalamine.Experimental
LovastatinThe metabolism of Codeine can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Codeine is combined with Loxapine.Approved
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Codeine.Approved, Investigational
LuliconazoleThe serum concentration of Codeine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Codeine can be increased when combined with Lumacaftor.Approved
LumateperoneThe risk or severity of adverse effects can be increased when Codeine is combined with Lumateperone.Investigational
LumefantrineThe therapeutic efficacy of Codeine can be decreased when used in combination with Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Codeine is combined with Lurasidone.Approved, Investigational
LymecyclineThe risk or severity of adverse effects can be increased when Codeine is combined with Lymecycline.Approved, Investigational
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Codeine.Illicit, Investigational, Withdrawn
m-ChlorophenylpiperazineThe risk or severity of adverse effects can be increased when Codeine is combined with m-Chlorophenylpiperazine.Investigational
Magnesium acetateThe risk or severity of adverse effects can be increased when Codeine is combined with Magnesium acetate.Approved
Magnesium acetate tetrahydrateThe risk or severity of adverse effects can be increased when Codeine is combined with Magnesium acetate tetrahydrate.Approved
Magnesium Aluminum SilicateThe risk or severity of adverse effects can be increased when Codeine is combined with Magnesium Aluminum Silicate.Approved
Magnesium aspartateThe risk or severity of adverse effects can be increased when Codeine is combined with Magnesium aspartate.Experimental
Magnesium carbonateThe risk or severity of adverse effects can be increased when Codeine is combined with Magnesium carbonate.Approved, Investigational
Magnesium cationThe risk or severity of adverse effects can be increased when Codeine is combined with Magnesium cation.Approved, Nutraceutical
Magnesium chlorideThe risk or severity of adverse effects can be increased when Codeine is combined with Magnesium chloride.Approved
Magnesium citrateThe risk or severity of adverse effects can be increased when Codeine is combined with Magnesium citrate.Approved
Magnesium gluconateThe risk or severity of adverse effects can be increased when Codeine is combined with Magnesium gluconate.Approved, Investigational
Magnesium glycinateThe risk or severity of adverse effects can be increased when Codeine is combined with Magnesium glycinate.Approved
Magnesium hydroxideThe risk or severity of adverse effects can be increased when Codeine is combined with Magnesium hydroxide.Approved, Investigational
Magnesium orotateThe risk or severity of adverse effects can be increased when Codeine is combined with Magnesium orotate.Experimental
Magnesium oxideThe risk or severity of adverse effects can be increased when Codeine is combined with Magnesium oxide.Approved
Magnesium peroxideThe therapeutic efficacy of Magnesium peroxide can be decreased when used in combination with Codeine.Experimental
Magnesium phosphateThe risk or severity of adverse effects can be increased when Codeine is combined with Magnesium phosphate.Experimental
Magnesium silicateThe risk or severity of adverse effects can be increased when Codeine is combined with Magnesium silicate.Approved
Magnesium stearateThe risk or severity of adverse effects can be increased when Codeine is combined with Magnesium stearate.Investigational
Magnesium sulfateThe therapeutic efficacy of Codeine can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
Magnesium TrisilicateThe risk or severity of adverse effects can be increased when Codeine is combined with Magnesium Trisilicate.Approved
ManidipineThe therapeutic efficacy of Codeine can be decreased when used in combination with Manidipine.Approved, Investigational
MannitolThe therapeutic efficacy of Mannitol can be decreased when used in combination with Codeine.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Codeine.Approved, Investigational
MazaticolThe risk or severity of adverse effects can be increased when Mazaticol is combined with Codeine.Experimental
MazindolThe risk or severity of adverse effects can be increased when Codeine is combined with Mazindol.Approved, Investigational
MebanazineThe risk or severity of adverse effects can be increased when Codeine is combined with Mebanazine.Withdrawn
MebeverineThe risk or severity of adverse effects can be increased when Mebeverine is combined with Codeine.Approved, Investigational
MebicarThe risk or severity of adverse effects can be increased when Codeine is combined with Mebicar.Experimental
MebutamateThe risk or severity of adverse effects can be increased when Codeine is combined with Mebutamate.Approved
MebutizideThe therapeutic efficacy of Mebutizide can be decreased when used in combination with Codeine.Experimental
MecamylamineThe risk or severity of adverse effects can be increased when Codeine is combined with Mecamylamine.Approved, Investigational
MeclizineThe risk or severity of adverse effects can be increased when Codeine is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Codeine is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Codeine is combined with Medetomidine.Vet Approved
MedifoxamineThe risk or severity of adverse effects can be increased when Codeine is combined with Medifoxamine.Experimental
MefrusideThe therapeutic efficacy of Mefruside can be decreased when used in combination with Codeine.Experimental
MelatoninThe risk or severity of adverse effects can be increased when Codeine is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelitracenThe risk or severity of adverse effects can be increased when Codeine is combined with Melitracen.Experimental, Investigational
MelperoneThe risk or severity of adverse effects can be increased when Codeine is combined with Melperone.Approved, Investigational
MepenzolateThe risk or severity of adverse effects can be increased when Mepenzolate is combined with Codeine.Approved
MephedroneMephedrone may increase the analgesic activities of Codeine.Investigational
MephenesinThe risk or severity of adverse effects can be increased when Codeine is combined with Mephenesin.Approved
MephenoxaloneThe risk or severity of adverse effects can be increased when Codeine is combined with Mephenoxalone.Experimental
MephentermineMephentermine may increase the analgesic activities of Codeine.Approved
MephenytoinThe risk or severity of adverse effects can be increased when Codeine is combined with Mephenytoin.Investigational, Withdrawn
MeprobamateThe risk or severity of adverse effects can be increased when Codeine is combined with Meprobamate.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Codeine.Experimental
MersalylThe therapeutic efficacy of Mersalyl can be decreased when used in combination with Codeine.Approved
MesoridazineThe risk or severity of hypotension and central nervous system depression can be increased when Mesoridazine is combined with Codeine.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Codeine is combined with Metaxalone.Approved
MetergolineThe risk or severity of adverse effects can be increased when Codeine is combined with Metergoline.Experimental
MethacyclineThe risk or severity of adverse effects can be increased when Codeine is combined with Methacycline.Approved, Investigational
MethadoneThe therapeutic efficacy of Codeine can be decreased when used in combination with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Codeine is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineMethamphetamine may increase the analgesic activities of Codeine.Approved, Illicit
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Codeine.Approved, Investigational
MethapyrileneThe risk or severity of adverse effects can be increased when Codeine is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Codeine is combined with Methaqualone.Illicit, Withdrawn
MetharbitalThe risk or severity of adverse effects can be increased when Codeine is combined with Metharbital.Withdrawn
MethazolamideThe therapeutic efficacy of Methazolamide can be decreased when used in combination with Codeine.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Codeine is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Codeine is combined with Methohexital.Approved
MethotrimeprazineCodeine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MethoxyfluraneThe risk or severity of adverse effects can be increased when Codeine is combined with Methoxyflurane.Approved, Investigational, Vet Approved
MethoxyphenamineMethoxyphenamine may increase the analgesic activities of Codeine.Experimental
MethscopolamineThe risk or severity of adverse effects can be increased when Methscopolamine is combined with Codeine.Approved
MethsuximideThe risk or severity of adverse effects can be increased when Codeine is combined with Methsuximide.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Codeine.Approved
Methyl celluloseThe therapeutic efficacy of Methyl cellulose can be decreased when used in combination with Codeine.Approved
Methylene blueThe risk or severity of adverse effects can be increased when Codeine is combined with Methylene blue.Approved, Investigational
MethylpentynolThe risk or severity of adverse effects can be increased when Codeine is combined with Methylpentynol.Experimental
MethylphenidateThe risk or severity of adverse effects can be increased when Codeine is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Codeine is combined with Methylphenobarbital.Approved
Methylscopolamine bromideThe risk or severity of adverse effects can be increased when Methylscopolamine bromide is combined with Codeine.Approved
MethyprylonThe risk or severity of adverse effects can be increased when Codeine is combined with Methyprylon.Approved, Illicit, Withdrawn
MethysergideThe risk or severity of adverse effects can be increased when Codeine is combined with Methysergide.Approved
MeticraneThe therapeutic efficacy of Meticrane can be decreased when used in combination with Codeine.Experimental
MetixeneThe risk or severity of adverse effects can be increased when Metixene is combined with Codeine.Approved
MetoclopramideThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Codeine.Approved, Investigational
MetocurineThe risk or severity of adverse effects can be increased when Codeine is combined with Metocurine.Approved
Metocurine IodideThe risk or severity of adverse effects can be increased when Codeine is combined with Metocurine Iodide.Approved, Withdrawn
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Codeine.Approved
MetyrosineCodeine may increase the sedative activities of Metyrosine.Approved
MianserinThe risk or severity of adverse effects can be increased when Codeine is combined with Mianserin.Approved, Investigational
MibefradilThe metabolism of Codeine can be decreased when combined with Mibefradil.Investigational, Withdrawn
MiconazoleThe metabolism of Codeine can be decreased when combined with Miconazole.Approved, Investigational, Vet Approved
MicronomicinThe risk or severity of adverse effects can be increased when Codeine is combined with Micronomicin.Experimental
MidazolamThe risk or severity of adverse effects can be increased when Codeine is combined with Midazolam.Approved, Illicit
MidomafetamineThe risk or severity of adverse effects can be increased when Midomafetamine is combined with Codeine.Experimental, Illicit, Investigational
MifepristoneThe serum concentration of Codeine can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Milnacipran is combined with Codeine.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when Codeine is combined with Minaprine.Approved
Mineral oilThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Codeine.Approved, Vet Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Codeine.Approved, Investigational
MirabegronThe therapeutic efficacy of Codeine can be decreased when used in combination with Mirabegron.Approved
MirtazapineCodeine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Codeine can be decreased when it is combined with Mitotane.Approved
MivacuriumThe risk or severity of adverse effects can be increased when Codeine is combined with Mivacurium.Approved
MK-212The risk or severity of adverse effects can be increased when Codeine is combined with MK-212.Investigational
MMDAMMDA may increase the analgesic activities of Codeine.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Codeine is combined with Moclobemide.Approved, Investigational
ModafinilThe serum concentration of Codeine can be decreased when it is combined with Modafinil.Approved, Investigational
MolindoneThe risk or severity of adverse effects can be increased when Codeine is combined with Molindone.Approved
MoperoneThe risk or severity of adverse effects can be increased when Codeine is combined with Moperone.Experimental
MoricizineThe risk or severity of hypotension and central nervous system depression can be increased when Moricizine is combined with Codeine.Approved, Investigational, Withdrawn
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Codeine.Approved, Investigational
MosapramineThe risk or severity of adverse effects can be increased when Codeine is combined with Mosapramine.Experimental
MosaprideThe risk or severity of adverse effects can be increased when Codeine is combined with Mosapride.Investigational
MRK-409The risk or severity of adverse effects can be increased when Codeine is combined with MRK-409.Experimental
MuzolimineThe therapeutic efficacy of Muzolimine can be decreased when used in combination with Codeine.Experimental
N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamineThe risk or severity of adverse effects can be increased when Codeine is combined with N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine.Experimental
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Codeine.Approved, Investigational
NafcillinThe serum concentration of Codeine can be decreased when it is combined with Nafcillin.Approved, Investigational
NaftidrofurylThe risk or severity of adverse effects can be increased when Codeine is combined with Naftidrofuryl.Experimental
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Codeine.Approved
NaloxoneThe metabolism of Codeine can be decreased when combined with Naloxone.Approved, Vet Approved
NaltrexoneThe risk or severity of adverse effects can be increased when Codeine is combined with Naltrexone.Approved, Investigational, Vet Approved
NaluzotanThe risk or severity of adverse effects can be increased when Codeine is combined with Naluzotan.Investigational
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Codeine.Approved, Investigational
NaronaprideThe risk or severity of adverse effects can be increased when Codeine is combined with Naronapride.Investigational
NeamineThe risk or severity of adverse effects can be increased when Codeine is combined with Neamine.Experimental
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Codeine.Approved, Withdrawn
NefiracetamThe risk or severity of adverse effects can be increased when Codeine is combined with Nefiracetam.Investigational
NelfinavirThe serum concentration of Codeine can be decreased when it is combined with Nelfinavir.Approved
NeocitrullamonThe risk or severity of adverse effects can be increased when Codeine is combined with Neocitrullamon.Experimental
NeomycinThe risk or severity of adverse effects can be increased when Codeine is combined with Neomycin.Approved, Vet Approved
NeosaxitoxinThe risk or severity of adverse effects can be increased when Codeine is combined with Neosaxitoxin.Investigational
NetilmicinThe risk or severity of adverse effects can be increased when Codeine is combined with Netilmicin.Approved, Investigational
NetupitantThe serum concentration of Codeine can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe metabolism of Codeine can be increased when combined with Nevirapine.Approved
NialamideThe risk or severity of adverse effects can be increased when Codeine is combined with Nialamide.Withdrawn
NiaprazineThe risk or severity of adverse effects can be increased when Codeine is combined with Niaprazine.Experimental
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Codeine.Approved, Investigational
NicomorphineThe risk or severity of adverse effects can be increased when Codeine is combined with Nicomorphine.Experimental
NilotinibThe therapeutic efficacy of Codeine can be decreased when used in combination with Nilotinib.Approved, Investigational
NisoxetineThe risk or severity of adverse effects can be increased when Codeine is combined with Nisoxetine.Experimental
NitrazepamThe risk or severity of adverse effects can be increased when Codeine is combined with Nitrazepam.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Codeine is combined with Nitrous oxide.Approved, Vet Approved
NomifensineThe risk or severity of adverse effects can be increased when Codeine is combined with Nomifensine.Withdrawn
NordazepamThe risk or severity of adverse effects can be increased when Codeine is combined with Nordazepam.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Codeine is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Codeine.Approved
OctamoxinThe risk or severity of adverse effects can be increased when Codeine is combined with Octamoxin.Withdrawn
OlanzapineThe risk or severity of adverse effects can be increased when Codeine is combined with Olanzapine.Approved, Investigational
OlaparibThe metabolism of Codeine can be decreased when combined with Olaparib.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Codeine is combined with Olopatadine.Approved
OndansetronThe risk or severity of serotonin syndrome can be increased when Ondansetron is combined with Codeine.Approved
OpipramolThe risk or severity of adverse effects can be increased when Codeine is combined with Opipramol.Investigational
OpiumThe risk or severity of adverse effects can be increased when Codeine is combined with Opium.Approved, Illicit
OrphenadrineCodeine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OrvepitantThe risk or severity of adverse effects can be increased when Codeine is combined with Orvepitant.Investigational
OsanetantThe risk or severity of adverse effects can be increased when Codeine is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Codeine can be increased when it is combined with Osimertinib.Approved
OtiloniumThe risk or severity of adverse effects can be increased when Otilonium is combined with Codeine.Experimental, Investigational
OxaflozaneThe risk or severity of adverse effects can be increased when Codeine is combined with Oxaflozane.Experimental
OxaprotilineThe risk or severity of adverse effects can be increased when Codeine is combined with Oxaprotiline.Experimental
OxazepamThe risk or severity of adverse effects can be increased when Codeine is combined with Oxazepam.Approved
OxcarbazepineThe serum concentration of Codeine can be decreased when it is combined with Oxcarbazepine.Approved
OxiracetamThe risk or severity of adverse effects can be increased when Codeine is combined with Oxiracetam.Experimental
OxitriptanThe risk or severity of adverse effects can be increased when Codeine is combined with Oxitriptan.Approved, Investigational, Nutraceutical
OxitropiumThe risk or severity of adverse effects can be increased when Oxitropium is combined with Codeine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Codeine is combined with Oxprenolol.Approved
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Codeine.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Codeine.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Codeine is combined with Oxymorphone.Approved, Investigational, Vet Approved
OxypertineThe risk or severity of adverse effects can be increased when Codeine is combined with Oxypertine.Experimental
OxyphencyclimineThe risk or severity of adverse effects can be increased when Oxyphencyclimine is combined with Codeine.Approved
OxyphenisatinThe therapeutic efficacy of Oxyphenisatin can be decreased when used in combination with Codeine.Investigational, Withdrawn
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Codeine.Approved
OxytetracyclineThe risk or severity of adverse effects can be increased when Codeine is combined with Oxytetracycline.Approved, Investigational, Vet Approved
PalbociclibThe serum concentration of Codeine can be increased when it is combined with Palbociclib.Approved, Investigational
PaliperidoneThe risk or severity of adverse effects can be increased when Codeine is combined with Paliperidone.Approved
PalonosetronThe risk or severity of adverse effects can be increased when Codeine is combined with Palonosetron.Approved, Investigational
PancuroniumThe risk or severity of adverse effects can be increased when Codeine is combined with Pancuronium.Approved
PanobinostatThe serum concentration of Codeine can be increased when it is combined with Panobinostat.Approved, Investigational
ParaldehydeCodeine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParamethadioneThe risk or severity of adverse effects can be increased when Codeine is combined with Paramethadione.Approved
PargylineThe risk or severity of adverse effects can be increased when Codeine is combined with Pargyline.Approved
ParomomycinThe risk or severity of adverse effects can be increased when Codeine is combined with Paromomycin.Approved, Investigational
ParoxetineThe therapeutic efficacy of Codeine can be decreased when used in combination with Paroxetine.Approved, Investigational
Peginterferon alfa-2bThe serum concentration of Codeine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PegvisomantThe therapeutic efficacy of Pegvisomant can be decreased when used in combination with Codeine.Approved
PenbutololThe risk or severity of adverse effects can be increased when Codeine is combined with Penbutolol.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Codeine is combined with Penfluridol.Experimental
PenimepicyclineThe risk or severity of adverse effects can be increased when Codeine is combined with Penimepicycline.Experimental
PentaerithritylThe therapeutic efficacy of Pentaerithrityl can be decreased when used in combination with Codeine.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Codeine.Approved, Vet Approved
PenthienateThe risk or severity of adverse effects can be increased when Penthienate is combined with Codeine.Experimental
PentobarbitalThe metabolism of Codeine can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Codeine.Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Codeine.Approved
PerazineThe risk or severity of hypotension and central nervous system depression can be increased when Perazine is combined with Codeine.Approved, Investigational
PergolideThe risk or severity of adverse effects can be increased when Codeine is combined with Pergolide.Approved, Investigational, Vet Approved, Withdrawn
PerospironeThe risk or severity of adverse effects can be increased when Codeine is combined with Perospirone.Approved
PerphenazineThe risk or severity of hypotension and central nervous system depression can be increased when Perphenazine is combined with Codeine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Codeine.Approved
PhenacemideThe risk or severity of adverse effects can be increased when Codeine is combined with Phenacemide.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Codeine.Experimental
PhencyclidineThe risk or severity of adverse effects can be increased when Codeine is combined with Phencyclidine.Illicit
PhenelzineThe risk or severity of adverse effects can be increased when Codeine is combined with Phenelzine.Approved
PhenethylamineThe risk or severity of adverse effects can be increased when Codeine is combined with Phenethylamine.Experimental
PheneturideThe risk or severity of adverse effects can be increased when Codeine is combined with Pheneturide.Experimental
PhenglutarimideThe risk or severity of adverse effects can be increased when Phenglutarimide is combined with Codeine.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Codeine is combined with Phenibut.Experimental
PheniprazineThe risk or severity of adverse effects can be increased when Codeine is combined with Pheniprazine.Withdrawn
PhenobarbitalThe serum concentration of Codeine can be decreased when it is combined with Phenobarbital.Approved, Investigational
PhenolphthaleinThe therapeutic efficacy of Phenolphthalein can be decreased when used in combination with Codeine.Approved, Withdrawn
PhenoperidineThe risk or severity of adverse effects can be increased when Codeine is combined with Phenoperidine.Experimental
PhenoxypropazineThe risk or severity of adverse effects can be increased when Codeine is combined with Phenoxypropazine.Withdrawn
PhenprobamateThe risk or severity of adverse effects can be increased when Codeine is combined with Phenprobamate.Experimental
PhensuximideThe risk or severity of adverse effects can be increased when Codeine is combined with Phensuximide.Approved
PhentermineThe risk or severity of adverse effects can be increased when Phentermine is combined with Codeine.Approved, Illicit
Phenylbutyric acidThe therapeutic efficacy of Codeine can be decreased when used in combination with Phenylbutyric acid.Approved, Investigational
PhenytoinThe serum concentration of Codeine can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PiclozotanThe risk or severity of adverse effects can be increased when Codeine is combined with Piclozotan.Investigational
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Codeine.Approved
PimavanserinThe risk or severity of adverse effects can be increased when Codeine is combined with Pimavanserin.Approved, Investigational
PimozideThe risk or severity of adverse effects can be increased when Codeine is combined with Pimozide.Approved
PinazepamThe risk or severity of adverse effects can be increased when Codeine is combined with Pinazepam.Experimental
PindololThe risk or severity of adverse effects can be increased when Codeine is combined with Pindolol.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Codeine is combined with Pipamperone.Approved, Investigational
PipecuroniumThe risk or severity of adverse effects can be increased when Codeine is combined with Pipecuronium.Approved
PipenzolateThe risk or severity of adverse effects can be increased when Pipenzolate is combined with Codeine.Experimental
PiperidolateThe risk or severity of adverse effects can be increased when Piperidolate is combined with Codeine.Experimental
PipotiazineThe risk or severity of hypotension and central nervous system depression can be increased when Pipotiazine is combined with Codeine.Approved, Investigational
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Codeine.Approved
PiretanideThe therapeutic efficacy of Piretanide can be decreased when used in combination with Codeine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Codeine.Approved, Investigational
PirlimycinThe risk or severity of adverse effects can be increased when Codeine is combined with Pirlimycin.Vet Approved
PirlindoleThe risk or severity of adverse effects can be increased when Codeine is combined with Pirlindole.Approved
PitolisantThe serum concentration of Codeine can be decreased when it is combined with Pitolisant.Approved, Investigational
PivagabineThe risk or severity of adverse effects can be increased when Codeine is combined with Pivagabine.Investigational
PivhydrazineThe risk or severity of adverse effects can be increased when Codeine is combined with Pivhydrazine.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Codeine is combined with Pizotifen.Approved
Plantago seedThe therapeutic efficacy of Plantago seed can be decreased when used in combination with Codeine.Approved, Investigational
PlazomicinThe risk or severity of adverse effects can be increased when Codeine is combined with Plazomicin.Approved, Investigational
PlecanatideThe therapeutic efficacy of Plecanatide can be decreased when used in combination with Codeine.Approved, Investigational
PoldineThe risk or severity of adverse effects can be increased when Poldine is combined with Codeine.Experimental
PolycarbophilThe therapeutic efficacy of Polycarbophil can be decreased when used in combination with Codeine.Approved
Polyethylene glycolThe therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Codeine.Approved, Vet Approved
Polymyxin B SulfateThe risk or severity of adverse effects can be increased when Codeine is combined with Polymyxin B Sulfate.Approved, Vet Approved
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Codeine.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Codeine is combined with Pomalidomide.Approved
PosaconazoleThe metabolism of Codeine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PotassiumThe therapeutic efficacy of Potassium can be decreased when used in combination with Codeine.Approved, Experimental
Potassium acetateThe therapeutic efficacy of Potassium acetate can be decreased when used in combination with Codeine.Approved, Investigational
Potassium cationThe therapeutic efficacy of Potassium cation can be decreased when used in combination with Codeine.Approved, Investigational
Potassium CitrateThe therapeutic efficacy of Potassium Citrate can be decreased when used in combination with Codeine.Approved, Investigational, Vet Approved
PramipexoleCodeine may increase the sedative activities of Pramipexole.Approved, Investigational
PrazepamThe risk or severity of adverse effects can be increased when Codeine is combined with Prazepam.Approved, Illicit
PregabalinThe therapeutic efficacy of Codeine can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PridinolThe risk or severity of adverse effects can be increased when Codeine is combined with Pridinol.Experimental
PrifiniumThe risk or severity of adverse effects can be increased when Prifinium is combined with Codeine.Experimental
PrimidoneThe serum concentration of Codeine can be decreased when it is combined with Primidone.Approved, Vet Approved
ProcainamideThe risk or severity of adverse effects can be increased when Codeine is combined with Procainamide.Approved
ProcaineThe risk or severity of adverse effects can be increased when Codeine is combined with Procaine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Codeine is combined with Procarbazine.Approved, Investigational
ProchlorperazineThe risk or severity of hypotension and central nervous system depression can be increased when Prochlorperazine is combined with Codeine.Approved, Vet Approved
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Codeine.Approved
ProgabideThe risk or severity of adverse effects can be increased when Codeine is combined with Progabide.Approved, Investigational
PromazineThe risk or severity of hypotension and central nervous system depression can be increased when Promazine is combined with Codeine.Approved, Vet Approved
PromethazineThe risk or severity of hypotension and central nervous system depression can be increased when Promethazine is combined with Codeine.Approved, Investigational
PropafenoneThe therapeutic efficacy of Codeine can be decreased when used in combination with Propafenone.Approved
PropanididThe risk or severity of adverse effects can be increased when Codeine is combined with Propanidid.Experimental
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Codeine.Approved
PropericiazineThe risk or severity of hypotension and central nervous system depression can be increased when Propericiazine is combined with Codeine.Approved, Investigational
PropiomazineThe risk or severity of adverse effects can be increased when Codeine is combined with Propiomazine.Approved
PropiopromazineThe risk or severity of hypotension and central nervous system depression can be increased when Propiopromazine is combined with Codeine.Vet Approved
PropiverineThe risk or severity of adverse effects can be increased when Propiverine is combined with Codeine.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Codeine is combined with Propofol.Approved, Investigational, Vet Approved
ProthipendylThe risk or severity of adverse effects can be increased when Codeine is combined with Prothipendyl.Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Codeine.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Codeine is combined with Proxibarbal.Experimental
PrucaloprideThe therapeutic efficacy of Prucalopride can be decreased when used in combination with Codeine.Approved
PRX-08066The risk or severity of adverse effects can be increased when Codeine is combined with PRX-08066.Investigational
PseudoephedrinePseudoephedrine may increase the analgesic activities of Codeine.Approved
PsilocybineThe risk or severity of adverse effects can be increased when Codeine is combined with Psilocybine.Investigational
PuromycinThe risk or severity of adverse effects can be increased when Codeine is combined with Puromycin.Experimental
PyrantelThe risk or severity of adverse effects can be increased when Codeine is combined with Pyrantel.Approved, Vet Approved
PyrithyldioneThe risk or severity of adverse effects can be increased when Codeine is combined with Pyrithyldione.Experimental
QuazepamThe risk or severity of adverse effects can be increased when Codeine is combined with Quazepam.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Codeine is combined with Quetiapine.Approved
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Codeine.Approved
QuinidineThe therapeutic efficacy of Codeine can be decreased when used in combination with Quinidine.Approved, Investigational
QuinineThe metabolism of Codeine can be increased when combined with Quinine.Approved
QuinupramineThe risk or severity of adverse effects can be increased when Codeine is combined with Quinupramine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Codeine is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Codeine is combined with Ramelteon.Approved, Investigational
RamosetronThe therapeutic efficacy of Ramosetron can be decreased when used in combination with Codeine.Approved, Investigational
RapacuroniumThe risk or severity of adverse effects can be increased when Codeine is combined with Rapacuronium.Withdrawn
RasagilineThe risk or severity of adverse effects can be increased when Codeine is combined with Rasagiline.Approved
ReboxetineThe risk or severity of adverse effects can be increased when Codeine is combined with Reboxetine.Approved, Investigational
RemacemideThe risk or severity of adverse effects can be increased when Codeine is combined with Remacemide.Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Codeine is combined with Remifentanil.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Codeine is combined with Remoxipride.Approved, Withdrawn
RenzaprideThe risk or severity of adverse effects can be increased when Codeine is combined with Renzapride.Investigational
RepinotanThe risk or severity of adverse effects can be increased when Codeine is combined with Repinotan.Investigational
ReposalThe risk or severity of adverse effects can be increased when Codeine is combined with Reposal.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Codeine.Approved, Investigational
RevefenacinThe risk or severity of adverse effects can be increased when Revefenacin is combined with Codeine.Investigational
RheinThe therapeutic efficacy of Codeine can be decreased when used in combination with Rhein.Experimental
RibostamycinThe risk or severity of adverse effects can be increased when Codeine is combined with Ribostamycin.Approved, Investigational
RifampicinThe serum concentration of Codeine can be decreased when it is combined with Rifampicin.Approved
RifamycinThe metabolism of Codeine can be increased when combined with Rifamycin.Investigational
RifapentineThe metabolism of Codeine can be increased when combined with Rifapentine.Approved, Investigational
RifaximinThe metabolism of Codeine can be increased when combined with Rifaximin.Approved, Investigational
RiluzoleThe risk or severity of adverse effects can be increased when Codeine is combined with Riluzole.Approved, Investigational
RimexoloneThe metabolism of Codeine can be increased when combined with Rimexolone.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Codeine.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Codeine is combined with Ritanserin.Investigational
RitobegronRitobegron may increase the analgesic activities of Codeine.Investigational
RitonavirThe therapeutic efficacy of Codeine can be decreased when used in combination with Ritonavir.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Codeine.Approved
RociverineThe risk or severity of adverse effects can be increased when Rociverine is combined with Codeine.Experimental
RocuroniumThe risk or severity of adverse effects can be increased when Codeine is combined with Rocuronium.Approved
RolapitantThe therapeutic efficacy of Codeine can be decreased when used in combination with Rolapitant.Approved, Investigational
RolipramThe risk or severity of adverse effects can be increased when Codeine is combined with Rolipram.Investigational
RolitetracyclineThe risk or severity of adverse effects can be increased when Codeine is combined with Rolitetracycline.Approved
RolofyllineThe therapeutic efficacy of Rolofylline can be decreased when used in combination with Codeine.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Codeine is combined with Romifidine.Vet Approved
RopiniroleCodeine may increase the sedative activities of Ropinirole.Approved, Investigational
RotigotineCodeine may increase the sedative activities of Rotigotine.Approved
RP-5063The risk or severity of adverse effects can be increased when Codeine is combined with RP-5063.Investigational
RucaparibThe therapeutic efficacy of Codeine can be decreased when used in combination with Rucaparib.Approved, Investigational
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Codeine.Approved
SafinamideThe risk or severity of adverse effects can be increased when Codeine is combined with Safinamide.Approved, Investigational
SafrazineThe risk or severity of adverse effects can be increased when Codeine is combined with Safrazine.Withdrawn
SaquinavirThe metabolism of Codeine can be decreased when combined with Saquinavir.Approved, Investigational
SaredutantThe risk or severity of adverse effects can be increased when Codeine is combined with Saredutant.Investigational
SarilumabThe therapeutic efficacy of Codeine can be decreased when used in combination with Sarilumab.Approved, Investigational
SarpogrelateThe risk or severity of adverse effects can be increased when Codeine is combined with Sarpogrelate.Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Codeine is combined with Scopolamine.Approved, Investigational
SecobarbitalThe risk or severity of adverse effects can be increased when Codeine is combined with Secobarbital.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Codeine is combined with Selegiline.Approved, Investigational, Vet Approved
SennosidesThe therapeutic efficacy of Sennosides can be decreased when used in combination with Codeine.Approved
SerotoninThe risk or severity of adverse effects can be increased when Codeine is combined with Serotonin.Investigational, Nutraceutical
SertindoleThe risk or severity of adverse effects can be increased when Codeine is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe therapeutic efficacy of Codeine can be decreased when used in combination with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Codeine is combined with Sevoflurane.Approved, Vet Approved
SibutramineThe risk or severity of adverse effects can be increased when Codeine is combined with Sibutramine.Approved, Illicit, Investigational, Withdrawn
SiltuximabThe serum concentration of Codeine can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Codeine can be increased when it is combined with Simeprevir.Approved
SisomicinThe risk or severity of adverse effects can be increased when Codeine is combined with Sisomicin.Investigational
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Codeine.Approved
Sodium phosphate, monobasicThe therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Codeine.Approved
Sodium sulfateThe therapeutic efficacy of Sodium sulfate can be decreased when used in combination with Codeine.Approved, Vet Approved
Sodium tartrateThe therapeutic efficacy of Sodium tartrate can be decreased when used in combination with Codeine.Approved
SolifenacinThe risk or severity of adverse effects can be increased when Solifenacin is combined with Codeine.Approved
SorbitolThe therapeutic efficacy of Sorbitol can be decreased when used in combination with Codeine.Approved
SpiradolineThe therapeutic efficacy of Spiradoline can be decreased when used in combination with Codeine.Investigational
SpironolactoneThe therapeutic efficacy of Spironolactone can be decreased when used in combination with Codeine.Approved
St. John's WortThe serum concentration of Codeine can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe serum concentration of Codeine can be increased when it is combined with Stiripentol.Approved
StreptomycinThe risk or severity of adverse effects can be increased when Codeine is combined with Streptomycin.Approved, Vet Approved
StyramateThe risk or severity of adverse effects can be increased when Codeine is combined with Styramate.Experimental
SuccinylcholineThe risk or severity of bradycardia can be increased when Succinylcholine is combined with Codeine.Approved
SufentanilThe risk or severity of adverse effects can be increased when Codeine is combined with Sufentanil.Approved, Investigational
SulconazoleThe therapeutic efficacy of Codeine can be decreased when used in combination with Sulconazole.Approved
SulpirideThe risk or severity of adverse effects can be increased when Codeine is combined with Sulpiride.Approved, Investigational
SulthiameThe risk or severity of adverse effects can be increased when Codeine is combined with Sulthiame.Experimental
SultoprideThe risk or severity of adverse effects can be increased when Codeine is combined with Sultopride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Codeine.Approved, Investigational
SuvorexantCodeine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
TalbutalThe risk or severity of adverse effects can be increased when Codeine is combined with Talbutal.Approved, Illicit
TalopramThe risk or severity of adverse effects can be increased when Codeine is combined with Talopram.Experimental
TandospironeThe risk or severity of adverse effects can be increased when Codeine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Codeine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Codeine is combined with Tasimelteon.Approved, Investigational
TD-8954The risk or severity of adverse effects can be increased when Codeine is combined with TD-8954.Investigational
Tedizolid phosphateThe risk or severity of adverse effects can be increased when Codeine is combined with Tedizolid phosphate.Approved
TegaserodThe risk or severity of adverse effects can be increased when Codeine is combined with Tegaserod.Approved, Investigational, Withdrawn
TelaprevirThe metabolism of Codeine can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Codeine can be decreased when combined with Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Codeine.Approved, Investigational
TerbinafineThe therapeutic efficacy of Codeine can be decreased when used in combination with Terbinafine.Approved, Investigational, Vet Approved
TerfenadineThe risk or severity of adverse effects can be increased when Terfenadine is combined with Codeine.Approved, Withdrawn
Testosterone propionateThe serum concentration of Codeine can be decreased when it is combined with Testosterone propionate.Approved, Investigational, Vet Approved, Withdrawn
TetracyclineThe risk or severity of adverse effects can be increased when Codeine is combined with Tetracycline.Approved, Vet Approved
TetrahydrocannabivarinThe risk or severity of adverse effects can be increased when Codeine is combined with Tetrahydrocannabivarin.Investigational
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Codeine is combined with Tetrahydropalmatine.Investigational
TetrazepamThe risk or severity of adverse effects can be increased when Codeine is combined with Tetrazepam.Experimental
TetrodotoxinThe risk or severity of adverse effects can be increased when Codeine is combined with Tetrodotoxin.Investigational
ThalidomideCodeine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheobromineThe therapeutic efficacy of Theobromine can be decreased when used in combination with Codeine.Approved, Investigational
ThiamylalThe risk or severity of adverse effects can be increased when Codeine is combined with Thiamylal.Approved, Vet Approved
ThiazinamThe risk or severity of hypotension and central nervous system depression can be increased when Thiazinam is combined with Codeine.Experimental
ThiethylperazineThe risk or severity of hypotension and central nervous system depression can be increased when Thiethylperazine is combined with Codeine.Withdrawn
ThiocolchicosideThe risk or severity of adverse effects can be increased when Codeine is combined with Thiocolchicoside.Approved, Investigational
ThiopentalThe risk or severity of adverse effects can be increased when Codeine is combined with Thiopental.Approved, Vet Approved
ThiopropazateThe risk or severity of adverse effects can be increased when Codeine is combined with Thiopropazate.Experimental
ThioproperazineThe risk or severity of hypotension and central nervous system depression can be increased when Thioproperazine is combined with Codeine.Approved
ThioridazineThe therapeutic efficacy of Codeine can be decreased when used in combination with Thioridazine.Approved, Withdrawn
ThiothixeneThe therapeutic efficacy of Codeine can be decreased when used in combination with Thiothixene.Approved
ThonzylamineThe risk or severity of adverse effects can be increased when Thonzylamine is combined with Codeine.Approved
TiagabineThe risk or severity of adverse effects can be increased when Codeine is combined with Tiagabine.Approved, Investigational
TianeptineThe risk or severity of adverse effects can be increased when Codeine is combined with Tianeptine.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Codeine is combined with Tiapride.Approved, Investigational
TicagrelorThe therapeutic efficacy of Codeine can be decreased when used in combination with Ticagrelor.Approved
TicrynafenThe therapeutic efficacy of Ticrynafen can be decreased when used in combination with Codeine.Withdrawn
Tiemonium iodideThe risk or severity of adverse effects can be increased when Tiemonium iodide is combined with Codeine.Experimental
TigecyclineThe risk or severity of adverse effects can be increased when Codeine is combined with Tigecycline.Approved
TiletamineThe risk or severity of adverse effects can be increased when Codeine is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Codeine.Experimental
TimepidiumThe risk or severity of adverse effects can be increased when Timepidium is combined with Codeine.Experimental
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Codeine.Approved
TipranavirThe therapeutic efficacy of Codeine can be decreased when used in combination with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of adverse effects can be increased when Codeine is combined with Tizanidine.Approved, Investigational
TobramycinThe risk or severity of adverse effects can be increased when Codeine is combined with Tobramycin.Approved, Investigational
TocilizumabThe serum concentration of Codeine can be decreased when it is combined with Tocilizumab.Approved
TofisopamThe risk or severity of adverse effects can be increased when Codeine is combined with Tofisopam.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Codeine is combined with Tolcapone.Approved, Withdrawn
ToloxatoneThe risk or severity of adverse effects can be increased when Codeine is combined with Toloxatone.Approved
TolperisoneThe risk or severity of adverse effects can be increased when Codeine is combined with Tolperisone.Approved, Investigational
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Codeine.Approved, Investigational
TolvaptanThe therapeutic efficacy of Tolvaptan can be decreased when used in combination with Codeine.Approved
TopiramateThe risk or severity of adverse effects can be increased when Codeine is combined with Topiramate.Approved
TorasemideThe therapeutic efficacy of Torasemide can be decreased when used in combination with Codeine.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Codeine.Approved, Investigational
TramiprosateThe risk or severity of adverse effects can be increased when Codeine is combined with Tramiprosate.Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Codeine is combined with Tranylcypromine.Approved, Investigational
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Codeine.Approved, Investigational
TriamtereneThe therapeutic efficacy of Triamterene can be decreased when used in combination with Codeine.Approved
TriazolamThe risk or severity of adverse effects can be increased when Codeine is combined with Triazolam.Approved, Investigational
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Codeine is combined with Tricaine methanesulfonate.Vet Approved
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Codeine.Approved, Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Codeine is combined with Trichloroethylene.Approved
TriclofosThe risk or severity of adverse effects can be increased when Codeine is combined with Triclofos.Withdrawn
TridihexethylThe risk or severity of adverse effects can be increased when Tridihexethyl is combined with Codeine.Withdrawn
TrifluoperazineThe risk or severity of hypotension and central nervous system depression can be increased when Trifluoperazine is combined with Codeine.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Codeine is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of hypotension and central nervous system depression can be increased when Triflupromazine is combined with Codeine.Approved, Vet Approved
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Codeine.Approved
TrimebutineThe risk or severity of adverse effects can be increased when Trimebutine is combined with Codeine.Approved
TrimethadioneThe risk or severity of adverse effects can be increased when Codeine is combined with Trimethadione.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Codeine.Approved, Investigational
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Codeine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Codeine is combined with Triprolidine.Approved
TroleandomycinThe metabolism of Codeine can be decreased when combined with Troleandomycin.Approved
TropatepineThe risk or severity of adverse effects can be increased when Tropatepine is combined with Codeine.Experimental
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Codeine.Approved, Investigational
TropisetronThe risk or severity of adverse effects can be increased when Codeine is combined with Tropisetron.Approved, Investigational
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Codeine.Approved
TubocurarineThe risk or severity of adverse effects can be increased when Codeine is combined with Tubocurarine.Approved
UlaritideThe therapeutic efficacy of Ularitide can be decreased when used in combination with Codeine.Investigational
UmeclidiniumThe risk or severity of adverse effects can be increased when Umeclidinium is combined with Codeine.Approved
UrapidilThe risk or severity of adverse effects can be increased when Codeine is combined with Urapidil.Investigational
VabicaserinThe risk or severity of adverse effects can be increased when Codeine is combined with Vabicaserin.Investigational
ValerianThe risk or severity of adverse effects can be increased when Codeine is combined with Valerian.Approved, Experimental, Investigational
ValnoctamideThe risk or severity of adverse effects can be increased when Codeine is combined with Valnoctamide.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Codeine is combined with Valproic Acid.Approved, Investigational
ValpromideThe risk or severity of adverse effects can be increased when Codeine is combined with Valpromide.Experimental
VancomycinThe risk or severity of adverse effects can be increased when Codeine is combined with Vancomycin.Approved
VecuroniumThe risk or severity of adverse effects can be increased when Codeine is combined with Vecuronium.Approved
VemurafenibThe serum concentration of Codeine can be decreased when it is combined with Vemurafenib.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Codeine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Codeine is combined with Veralipride.Experimental
VerapamilThe metabolism of Codeine can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Codeine is combined with Vigabatrin.Approved
VilazodoneThe therapeutic efficacy of Codeine can be decreased when used in combination with Vilazodone.Approved
ViloxazineThe risk or severity of adverse effects can be increased when Codeine is combined with Viloxazine.Approved, Investigational, Withdrawn
VinbarbitalThe risk or severity of adverse effects can be increased when Codeine is combined with Vinbarbital.Experimental
VinpocetineThe risk or severity of adverse effects can be increased when Codeine is combined with Vinpocetine.Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Codeine is combined with Vinyl ether.Experimental
VinylbitalThe risk or severity of adverse effects can be increased when Codeine is combined with Vinylbital.Experimental
VoriconazoleThe metabolism of Codeine can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Codeine.Approved, Investigational
WortmanninThe risk or severity of adverse effects can be increased when Codeine is combined with Wortmannin.Experimental
XipamideThe therapeutic efficacy of Xipamide can be decreased when used in combination with Codeine.Experimental
XP19986The risk or severity of adverse effects can be increased when Codeine is combined with XP19986.Investigational
XylazineThe risk or severity of adverse effects can be increased when Codeine is combined with Xylazine.Vet Approved
YKP-1358The risk or severity of adverse effects can be increased when Codeine is combined with YKP-1358.Investigational
YohimbineThe risk or severity of adverse effects can be increased when Codeine is combined with Yohimbine.Approved, Investigational, Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Codeine is combined with Zaleplon.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Codeine is combined with Ziconotide.Approved
ZidovudineThe serum concentration of Codeine can be decreased when it is combined with Zidovudine.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Codeine is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Codeine.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Codeine is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Codeine.Approved, Investigational
ZolpidemCodeine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Codeine is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Codeine is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Codeine is combined with Zotepine.Approved, Investigational, Withdrawn
ZuclopenthixolThe risk or severity of adverse effects can be increased when Codeine is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Take with food, food reduces irritation.
  • To avoid constipation: increase your daily intake of fiber (beans, whole grains, vegetables).

References

Synthesis Reference

Nagaraj R. Ayyangar, Anil R. Choudhary, Uttam R. Kalkote, Vasant K. Sharma, "Process for the preparation of codeine from morphine." U.S. Patent US4764615, issued May, 1912.

US4764615
General References
  1. Schroeder K, Fahey T: Over-the-counter medications for acute cough in children and adults in ambulatory settings. Cochrane Database Syst Rev. 2004 Oct 18;(4):CD001831. [PubMed:15495019]
  2. Vree TB, van Dongen RT, Koopman-Kimenai PM: Codeine analgesia is due to codeine-6-glucuronide, not morphine. Int J Clin Pract. 2000 Jul-Aug;54(6):395-8. [PubMed:11092114]
  3. Srinivasan V, Wielbo D, Tebbett IR: Analgesic effects of codeine-6-glucuronide after intravenous administration. Eur J Pain. 1997;1(3):185-90. [PubMed:15102399]
External Links
Human Metabolome Database
HMDB0004995
KEGG Drug
D03580
KEGG Compound
C06174
PubChem Compound
5284371
PubChem Substance
46507764
ChemSpider
4447447
BindingDB
50105098
ChEBI
16714
ChEMBL
CHEMBL485
Therapeutic Targets Database
DAP000213
PharmGKB
PA449088
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Codeine
ATC Codes
N02AA59 — Codeine, combinations excl. psycholepticsN02AA79 — Codeine, combinations with psycholepticsR05DA04 — Codeine
AHFS Codes
  • 48:08.00 — Antitussives
  • 28:08.08 — Opiate Agonists
MSDS
Download (52.5 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedBasic ScienceDrug Biotransformation / Membrane Transport1
1CompletedBasic ScienceGenotype-related Drug Metabolism1
1CompletedTreatmentConstipation Drug Induced / Healthy Volunteers1
1CompletedTreatmentDiabetic Neuropathies / Fibromyalgia / Major Depressive Disorder (MDD) / Vasomotor Symptoms1
1CompletedTreatmentPain4
1Not Yet RecruitingBasic ScienceCodeine / Metformin / Organic Cation Transporter 11
1Unknown StatusTreatmentMechanically Ventilated Neonates / Painful Procedures in Newborns1
1, 2CompletedTreatmentSickle Cell Disorders1
2CompletedTreatmentCervical Pain1
2RecruitingTreatmentPainful musculoskeletal conditions1
2, 3CompletedTreatmentIdiopathic Intracranial Hypertension (IIH)1
3CompletedSupportive CareAnalgesia After ED Discharge for Extremity Injuries1
3CompletedTreatmentMyopia1
3CompletedTreatmentPostoperative Dental Pain1
3TerminatedTreatmentPain1
4CompletedSupportive CarePain / Unspecified Adult Solid Tumor, Protocol Specific1
4CompletedTreatmentBack Pain / Osteoarthritis (OA)1
4CompletedTreatmentGastric Motility Disorder1
4CompletedTreatmentImpacted Third Molar Tooth1
4CompletedTreatmentPain1
4CompletedTreatmentPain / Tonsillitis1
4CompletedTreatmentPostcraniotomy Pain1
4CompletedTreatmentPostoperative pain1
4CompletedTreatmentTraumas1
4RecruitingTreatmentCervical Preparation / Pain / Pregnancy Termination1
4RecruitingTreatmentPostoperative pain1
4Unknown StatusTreatmentPostoperative Laminectomy Pain / Postoperative pain1
4WithdrawnBasic ScienceSickle Cell Disorders1
4WithdrawnTreatmentPain, Chronic1
Not AvailableCompletedDiagnosticGastric Emptying / Healthy Volunteers / Motility Disorders1
Not AvailableCompletedPreventionHeadaches1
Not AvailableCompletedTreatmentPain2
Not AvailableCompletedTreatmentPeriapical Abscess1
Not AvailableRecruitingTreatmentLow Back Pain (LBP)1
Not AvailableUnknown StatusTreatmentFracture Bone / Pain1

Pharmacoeconomics

Manufacturers
  • Roxane laboratories inc
Packagers
  • Actavis Group
  • Aidarex Pharmacuticals LLC
  • Amarin Pharmaceuticals
  • Amerisource Health Services Corp.
  • Amneal Pharmaceuticals
  • Apotheca Inc.
  • A-S Medication Solutions LLC
  • Athlon Pharmaceuticals Inc.
  • Barr Pharmaceuticals
  • BASF Corp.
  • Blansett Pharmacal Co. Inc.
  • Blenheim Pharmacal
  • Breckenridge Pharmaceuticals
  • Bryant Ranch Prepack
  • C.O. Truxton Inc.
  • Cardinal Health
  • Carlisle Laboratories Inc.
  • Centurion Labs
  • Century Pharmaceuticals Inc.
  • Cerovene Inc.
  • Comprehensive Consultant Services Inc.
  • Corepharma LLC
  • Coupler Enterprises Inc.
  • D.M. Graham Laboratories Inc.
  • DAVA Pharmaceuticals
  • Direct Dispensing Inc.
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • Duramed
  • Eon Labs
  • Glenmark Generics Ltd.
  • Golden State Medical Supply Inc.
  • Great Southern Laboratories
  • H and H Laboratories
  • H.J. Harkins Co. Inc.
  • Heartland Repack Services LLC
  • Hi Tech Pharmacal Co. Inc.
  • Hospira Inc.
  • Innoviant Pharmacy Inc.
  • Ivax Pharmaceuticals
  • Janssen-Ortho Inc.
  • Jerome Stevens Pharmaceuticals Inc.
  • Kaiser Foundation Hospital
  • Keltman Pharmaceuticals Inc.
  • Lake Erie Medical and Surgical Supply
  • Lannett Co. Inc.
  • Lehigh Valley Technologies Inc.
  • Liberty Pharmaceuticals
  • Major Pharmaceuticals
  • Mallinckrodt Inc.
  • Mckesson Corp.
  • MCR American Pharmaceuticals Inc.
  • Medvantx Inc.
  • Mikart Inc.
  • Murfreesboro Pharmaceutical Nursing Supply
  • Mutual Pharmaceutical Co.
  • Nexgen Pharma Inc.
  • Novartis AG
  • Nucare Pharmaceuticals Inc.
  • Ortho-McNeil-Janssen Pharmaceuticals Inc.
  • Palmetto Pharmaceuticals Inc.
  • Patient First Corp.
  • PCA LLC
  • PD-Rx Pharmaceuticals Inc.
  • Pharmaceutical Association
  • Pharmedix
  • Pharmpak Inc.
  • Physicians Total Care Inc.
  • Poly Pharmaceuticals Inc.
  • Preferred Pharmaceuticals Inc.
  • Prepackage Specialists
  • Prepak Systems Inc.
  • Qualitest
  • Ranbaxy Laboratories
  • Rebel Distributors Corp.
  • Redpharm Drug
  • Remedy Repack
  • Roxane Labs
  • Sandhills Packaging Inc.
  • SJ Pharmaceuticals LLC
  • Southwood Pharmaceuticals
  • St Mary's Medical Park Pharmacy
  • Stanley Pharmaceuticals Ltd.
  • Stat Rx Usa
  • Talbert Medical Management Corp.
  • Teva Pharmaceutical Industries Ltd.
  • TG United Inc.
  • UDL Laboratories
  • United Research Laboratories Inc.
  • Va Cmop Dallas
  • Valeant Ltd.
  • Vascondor Inc.
  • Veratex Corp.
  • Vintage Pharmaceuticals Inc.
  • Watson Pharmaceuticals
  • West-Ward Pharmaceuticals
  • Wockhardt Ltd.
Dosage forms
FormRouteStrength
SolutionOral
TabletOral
TabletOral300 mg/1
CapsuleOral
LiquidOral
Tablet, extended releaseOral
Tablet, extended releaseOral100 mg
Tablet, extended releaseOral150 mg
Tablet, extended releaseOral200 mg
Tablet, extended releaseOral50 mg
SolutionIntramuscular; Subcutaneous30 mg
SolutionIntramuscular; Subcutaneous60 mg
LiquidIntramuscular; Subcutaneous30 mg
SyrupOral25 mg
SyrupOral5 mg
TabletOral15 mg
TabletOral60 mg
SolutionOral15 mg/2.5mL
SolutionOral30 mg/5mL
TabletOral15 mg/1
TabletOral30 mg/1
TabletOral60 mg/1
SolutionOral10 mg
LiquidOral10 mg
TabletOral30 mg
SyrupOral
ElixirOral
KitOral
Suspension, extended releaseOral
SuspensionOral
Prices
Unit descriptionCostUnit
Codeine phosphate powder8.25USD g
Codeine Phosphate 30 mg/ml1.31USD ml
Codeine sulfate 60 mg tablet0.86USD tablet
Codeine sulfate 30 mg tablet0.76USD tablet
Codeine ph 30 mg/ml syringe0.54USD ml
Codeine ph 15 mg/ml syringe0.49USD ml
Codeine sulfate 15 mg tablet0.43USD tablet
Ratio-Codeine 30 mg Tablet0.09USD tablet
Ratio-Codeine 15 mg Tablet0.07USD tablet
Ratio-Codeine 5 mg/ml Syrup0.03USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US8062667No2009-03-292029-03-29Us
US8790700No2007-03-152027-03-15Us
US9066942No2012-01-032032-01-03Us
US6383471No1999-04-062019-04-06Us
US6248363No1999-11-232019-11-23Us
US9107921No2012-01-032032-01-03Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)157.5 °CPhysProp
boiling point (°C)250 °C at 2.20E+01 mm HgPhysProp
water solubility9000 mg/L (at 20 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP1.19AVDEEF,A ET AL. (1996)
logS-1.52ADME Research, USCD
pKa8.21 (at 25 °C)LIDE,DR (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.577 mg/mLALOGPS
logP1.2ALOGPS
logP1.34ChemAxon
logS-2.7ALOGPS
pKa (Strongest Acidic)13.78ChemAxon
pKa (Strongest Basic)9.19ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area41.93 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity84.6 m3·mol-1ChemAxon
Polarizability31.95 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9966
Blood Brain Barrier+0.9979
Caco-2 permeable+0.8867
P-glycoprotein substrateSubstrate0.8631
P-glycoprotein inhibitor IInhibitor0.5435
P-glycoprotein inhibitor IINon-inhibitor0.8724
Renal organic cation transporterInhibitor0.638
CYP450 2C9 substrateNon-substrate0.7698
CYP450 2D6 substrateSubstrate0.9274
CYP450 3A4 substrateSubstrate0.7796
CYP450 1A2 substrateNon-inhibitor0.6494
CYP450 2C9 inhibitorNon-inhibitor0.8866
CYP450 2D6 inhibitorInhibitor0.6978
CYP450 2C19 inhibitorNon-inhibitor0.8256
CYP450 3A4 inhibitorNon-inhibitor0.8899
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.747
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.9567
BiodegradationNot ready biodegradable0.9935
Rat acute toxicity2.8450 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8556
hERG inhibition (predictor II)Non-inhibitor0.8615
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Mass Spectrum (Electron Ionization)MSsplash10-01ot-3950000000-e80ecb11646b4da6aa92
LC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL Thermo Scientific) 60V, PositiveLC-MS/MSsplash10-0uxr-0973000000-87d07ddd2ed24b9598d7
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0udi-0009000000-d68b67071bf467a42afa
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0udi-0009000000-a298cedb776a11677cf7
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0udi-0459000000-1a92521b38ba51a7fa81
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0gc1-0940000000-68cae285315cfe9c7d0e
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0uxs-0910000000-b0c288c76c616e1a54d3
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0159-0390000000-ac30542a576060b3373c
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udi-0009000000-870de7833257cd342810
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udi-0009000000-8ece718ed46e5e439112
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udi-0139000000-7880499a47dbd2f41229
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0uxr-0973000000-87d07ddd2ed24b9598d7
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-015a-0920000000-4f676c9e2b42320493af
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0uxr-0910000000-e67964930533268605cd
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udi-0009000000-99b083bf48ae39e3cec6
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udi-0009000000-efebfbff05a4cb72fe32
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udi-0139000000-be0f9b6eaa028b54ad6c
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0uxr-0973000000-89bc81638a52beefd890
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-015a-0920000000-7eccc8e19d8d88b18128
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0uxr-0910000000-5809a9ed32210bcfa231
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0159-0390000000-a7469c01c0a4ff4179bf
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0uyi-1952000000-3db61b1a0c8cde5b8c82
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0lea-1940000000-b491506c23f09adaee8c
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0lea-1930000000-48dcc53ac80bf97d1f2d

Taxonomy

Description
This compound belongs to the class of organic compounds known as morphinans. These are polycyclic compounds with a four-ring skeleton with three condensed six-member rings forming a partially hydrogenated phenanthrene moiety, one of which is aromatic while the two others are alicyclic.
Kingdom
Organic compounds
Super Class
Alkaloids and derivatives
Class
Morphinans
Sub Class
Not Available
Direct Parent
Morphinans
Alternative Parents
Phenanthrenes and derivatives / Tetralins / Coumarans / Anisoles / Aralkylamines / Alkyl aryl ethers / Piperidines / Trialkylamines / Secondary alcohols / Oxacyclic compounds
show 3 more
Substituents
Morphinan / Phenanthrene / Tetralin / Coumaran / Anisole / Alkyl aryl ether / Aralkylamine / Piperidine / Benzenoid / Secondary alcohol
show 15 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
morphinane alkaloid, organic heteropentacyclic compound (CHEBI:16714) / Isoquinoline alkaloids (C06174)

Targets

Details
1. Mu-type opioid receptor
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Partial agonist
General Function
Voltage-gated calcium channel activity
Specific Function
Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone...
Gene Name
OPRM1
Uniprot ID
P35372
Uniprot Name
Mu-type opioid receptor
Molecular Weight
44778.855 Da
References
  1. Grond S, Sablotzki A: Clinical pharmacology of tramadol. Clin Pharmacokinet. 2004;43(13):879-923. [PubMed:15509185]
  2. Takahama K, Shirasaki T: Central and peripheral mechanisms of narcotic antitussives: codeine-sensitive and -resistant coughs. Cough. 2007 Jul 9;3:8. [PubMed:17620111]
  3. Freissmuth M, Beindl W, Kratzel M: Binding and structure-activity-relation of benzo[f]isoquinoline- and norcodeinone-derivatives at mu-opioid receptors in the rat cerebral cortex. Br J Pharmacol. 1993 Dec;110(4):1429-36. [PubMed:8306082]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Partial agonist
General Function
Opioid receptor activity
Specific Function
G-protein coupled opioid receptor that functions as receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as receptor for various synt...
Gene Name
OPRK1
Uniprot ID
P41145
Uniprot Name
Kappa-type opioid receptor
Molecular Weight
42644.665 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Takahama K, Shirasaki T: Central and peripheral mechanisms of narcotic antitussives: codeine-sensitive and -resistant coughs. Cough. 2007 Jul 9;3:8. [PubMed:17620111]
  4. Mignat C, Wille U, Ziegler A: Affinity profiles of morphine, codeine, dihydrocodeine and their glucuronides at opioid receptor subtypes. Life Sci. 1995;56(10):793-9. [PubMed:7885194]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Opioid receptor activity
Specific Function
G-protein coupled receptor that functions as receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine n...
Gene Name
OPRD1
Uniprot ID
P41143
Uniprot Name
Delta-type opioid receptor
Molecular Weight
40368.235 Da
References
  1. Ortiz MI, Castro-Olguin J, Pena-Samaniego N, Castaneda-Hernandez G: Probable activation of the opioid receptor-nitric oxide-cyclic GMP-K+ channels pathway by codeine. Pharmacol Biochem Behav. 2005 Dec;82(4):695-703. Epub 2006 Jan 4. [PubMed:16386786]
  2. Mignat C, Wille U, Ziegler A: Affinity profiles of morphine, codeine, dihydrocodeine and their glucuronides at opioid receptor subtypes. Life Sci. 1995;56(10):793-9. [PubMed:7885194]
  3. Loghin F, Popa DS, Socaciu C: Influence of glutethimide on rat brain mononucleotides by sub-chronic codeine treatment. J Cell Mol Med. 2001 Oct-Dec;5(4):409-16. [PubMed:12067475]
  4. Advenier C, Girard V, Naline E, Vilain P, Emonds-Alt X: Antitussive effect of SR 48968, a non-peptide tachykinin NK2 receptor antagonist. Eur J Pharmacol. 1993 Nov 30;250(1):169-71. [PubMed:8119316]
  5. Karlsson JA, Lanner AS, Persson CG: Airway opioid receptors mediate inhibition of cough and reflex bronchoconstriction in guinea pigs. J Pharmacol Exp Ther. 1990 Feb;252(2):863-8. [PubMed:2156065]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]

Enzymes

Details
1. Cytochrome P450 2D6
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Zhou SF: Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin Pharmacokinet. 2009;48(11):689-723. doi: 10.2165/11318030-000000000-00000. [PubMed:19817501]
  2. Duquette PH, Peterson FJ, Crankshaw DL, Lindemann NJ, Holtzman JL: Studies of the metabolic N- and O-demethylation of [6-3H]codeine. Drug Metab Dispos. 1983 Sep-Oct;11(5):477-80. [PubMed:6138234]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Duquette PH, Peterson FJ, Crankshaw DL, Lindemann NJ, Holtzman JL: Studies of the metabolic N- and O-demethylation of [6-3H]codeine. Drug Metab Dispos. 1983 Sep-Oct;11(5):477-80. [PubMed:6138234]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A7
Uniprot ID
P24462
Uniprot Name
Cytochrome P450 3A7
Molecular Weight
57525.03 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Glucuronosyltransferase activity
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds.Its unique specificity for 3,4-catechol estrogens and estriol su...
Gene Name
UGT2B7
Uniprot ID
P16662
Uniprot Name
UDP-glucuronosyltransferase 2B7
Molecular Weight
60694.12 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Glucuronosyltransferase activity
Specific Function
UDPGTs are of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isozyme is active on polyhydroxylated estrogens (such as...
Gene Name
UGT2B4
Uniprot ID
P06133
Uniprot Name
UDP-glucuronosyltransferase 2B4
Molecular Weight
60512.035 Da
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Steroid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the...
Gene Name
UGT1A1
Uniprot ID
P22309
Uniprot Name
UDP-glucuronosyltransferase 1-1
Molecular Weight
59590.91 Da
References
  1. Williams JA, Hyland R, Jones BC, Smith DA, Hurst S, Goosen TC, Peterkin V, Koup JR, Ball SE: Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8. doi: 10.1124/dmd.104.000794. Epub 2004 Aug 10. [PubMed:15304429]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Secondary active organic cation transmembrane transporter activity
Specific Function
Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnico...
Gene Name
SLC22A1
Uniprot ID
O15245
Uniprot Name
Solute carrier family 22 member 1
Molecular Weight
61153.345 Da
References
  1. Tzvetkov MV, dos Santos Pereira JN, Meineke I, Saadatmand AR, Stingl JC, Brockmoller J: Morphine is a substrate of the organic cation transporter OCT1 and polymorphisms in OCT1 gene affect morphine pharmacokinetics after codeine administration. Biochem Pharmacol. 2013 Sep 1;86(5):666-78. doi: 10.1016/j.bcp.2013.06.019. Epub 2013 Jul 5. [PubMed:23835420]

Drug created on June 13, 2005 07:24 / Updated on August 15, 2018 10:01